^
1d
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
P1b, N=65, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • bintrafusp alfa (M7824) • entinostat (SNDX-275) • BN-Brachyury
2d
neo-TN: Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
P2/3, N=310, Active, not recruiting, The Netherlands Cancer Institute | Trial primary completion date: Jun 2021 --> Jun 2022
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative
|
carboplatin • paclitaxel • doxorubicin hydrochloride • thiotepa
6d
Clinical • Enrollment open • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 negative • PD-L1 negative • ER negative • PGR negative
|
Abraxane (albumin-bound paclitaxel) • SG001
7d
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=37, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • RB1 positive • PGR negative
|
Verzenio (abemaciclib)
8d
[VIRTUAL] PROGRESSIVE INTERSTITIAL LUNG DISEASE IN A PATIENT WITH BREAST CANCER-ASSOCIATED ANTISYNTHETASE SYNDROME AND TIF-1-GAMMA ANTIBODIES (CHEST 2021)
Two months prior to her presentation, she was started on neoadjuvant chemotherapy with cyclophosphamide, doxorubicin and paclitaxel. Although uncommon, when TIF-1-Gamma antibodies are present in a patient with a cancer associated myopathy and ILD, progressive pulmonary findings may herald recurrent malignancy.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR negative
|
paclitaxel • doxorubicin hydrochloride
9d
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
P1, N=24, Recruiting, George T. Budd | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
|
HER-2 negative • ER negative • PGR negative
|
alpha-lactalbumin vaccine
10d
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Tecentriq (atezolizumab) • paclitaxel
10d
ARC-2: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (clinicaltrials.gov)
P1, N=35, Completed, Arcus Biosciences, Inc. | Active, not recruiting --> Completed | N=214 --> 35 | Trial completion date: Jul 2022 --> Jul 2021 | Trial primary completion date: Feb 2022 --> Jul 2021
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Abraxane (albumin-bound paclitaxel) • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928)
10d
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma (clinicaltrials.gov)
P2, N=30, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2027 --> Oct 2021 | Trial primary completion date: Aug 2022 --> Mar 2021
Trial completion • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • ER positive • ER negative • PGR negative
|
ONC201
12d
PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients (SABCS 2021)
Trial design: 3-stage open label randomised phase II/III trial of neoadjuvant paclitaxel and carboplatin +/- olaparib, followed by clinicians' choice of anthracycline regimen. The trial is open and enrolling patients to UK and international sites. Contact information : partner@addenbrookes.nhs.uk
Clinical • P2/3 data • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
HER-2 negative • ER negative • BRCA mutation
|
Lynparza (olaparib) • carboplatin • paclitaxel
12d
Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer (SABCS 2021)
With extended follow-up, pyrotinib plus capecitabine demonstrated statistically significant OS improvement compared with lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer after trastuzumab and chemotherapy. This updated analysis of overall survival in the PHOEBE trial reaffirmed pyrotinib plus capecitabine as an established treatment option in this patient population. Data are median (95% CI).
Clinical • P3 data • Combination therapy
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ERBB4 (erb-b2 receptor tyrosine kinase 4)
|
HER-2 positive • PGR negative
|
Herceptin (trastuzumab) • lapatinib • capecitabine • Irene (pyrotinib)
12d
Taxane with anthracycline versus taxane without anthracycline: An individual patient-level meta-analysis of 16,500 women with early-stage breast cancer in 13 randomised trials (SABCS 2021)
However, concerns about the increased risks of cardiac toxicity and leukaemia with anthracyclines have resulted in wider use of taxane chemotherapy schedules without anthracycline, in particular docetaxel-cyclophosphamide (DC)...The proportional reduction in recurrence was greatest in trials of concurrent Anth + DC versus DC (RR 0.66, 95%CI 0.55-0.79; p0.1... The addition of anthracycline to taxane chemotherapy, compared to taxane alone reduced the risk of breast cancer recurrence by 18% with larger proportional reductions in trials of DC ± concurrent Anth, in which the taxane dose was the same in both groups and the cumulative anthracycline dose was higher.
Retrospective data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
|
docetaxel • doxorubicin hydrochloride • epirubicin
12d
Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL (SABCS 2021)
A total of 160 pts will be randomly assigned (1:1) to receive abemaciclib (300 mg/day orally during each 28-day cycle) plus ET as per investigator’s criteria (either letrozole [2.5 mg/day orally] or fulvestrant [500 mg intramuscularly on days 1, 15 of cycle 1, and on day 1 thereafter], or paclitaxel (90 mg/m² intravenously on days 1, 8, 15). Both analyses, will be conducted with the Newcombe hybrid score method for confidence intervals. This trial was opened to accrual in May 2021.
Clinical • P2 data • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HR positive + HER-2 negative • PGR negative
|
paclitaxel • Verzenio (abemaciclib) • fulvestrant • letrozole
12d
The NAUTILUS trial (No Axillary sUrgical Treatment In clinically Lymph node negative patients after UltraSonography): A prospective multicenter randomized phase III trial (NCT04303715) (SABCS 2021)
As of July 9, 2021, 480 patients have been randomized. Target accrual of 1734 patients is expected to be complete by April 2023, with the primary endpoint analysis expected in 2028.
Clinical • P3 data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR negative • HR positive + HER-2 negative
12d
Phase III postneoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA (SABCS 2021)
Patients are randomized 1:1 to receive either SG 10 mg/kg body weight (days 1, 8 q3w for eight cycles) or treatment of physician´s choice (capecitabine 2000 mg/m² day 1-14 q21 or platinum-based chemotherapy i.e. carboplatin AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles or observation). Secondary endpoints include comparison of overall survival (OS, key secondary endpoint), distant disease-free survival, locoregional recurrences-free interval, safety, compliance, iDFS and OS according to stratified and - predefined subgroups, patient reported outcome, and quality of life between treatment arms. As of 21 st June 2021, 57/1200 patients have been randomized in Germany.
Clinical • P3 data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
carboplatin • capecitabine • Trodelvy (sacituzumab govitecan-hziy)
14d
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC (clinicaltrials.gov)
P1, N=20, Recruiting, Baylor Research Institute | Trial completion date: Sep 2021 --> Dec 2023 | Trial primary completion date: Sep 2021 --> Oct 2023
Clinical • Trial completion date • Trial primary completion date
|
ER (Estrogen receptor)
|
ER negative
|
Keytruda (pembrolizumab) • cisplatin • bortezomib
16d
[VIRTUAL] The use of neoadjuvant systemic therapy in early breast cancer as a guide to adjuvant treatment choices: a single institution review (COSA 2021)
This was particularly seen in patients with TNBC or Her2+ tumours with residual disease. Moving forward, more patients are likely to benefit from informed adjustment of adjuvant therapies, with available or emerging agents, following NSC.
Clinical • Review
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER negative
16d
[VIRTUAL] Charlson Comorbidity Index Guides Treatment Decisions For HER2 Positive Breast Cancer In Older Women. (ACS-CLINCON 2021)
The Charlson Comorbidity Index identifies patients over age 70 who may not benefit form systemic treatment for HER2+ Breast Cancer
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
16d
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HR negative • PGR expression
|
carboplatin • Ibrance (palbociclib) • paclitaxel
16d
Clinical • New P2 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 negative • PD-L1 negative • ER negative • PGR negative
|
Abraxane (albumin-bound paclitaxel) • SG001
21d
Journal
|
ER (Estrogen receptor) • FANCM (FA Complementation Group M)
|
ER negative
21d
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists. (PubMed, Histol Histopathol)
Furthermore, several pre-analytical and analytical variables might trouble the pathological identification of these clinically challenging cases. In this review, we sought to discuss the adversities that can be accounted for the pathological identification of ER-low breast cancers in real-world clinical practice, and to provide practical suggestions for the perfect ER testing in light of the most updated recommendations and guidelines.
Review • Journal
|
ER (Estrogen receptor)
|
ER negative • ER-L
23d
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER negative
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
24d
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Sep 2021 --> Dec 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative
|
methotrexate IV
24d
Safe-De: Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer (clinicaltrials.gov)
P=N/A, N=400, Not yet recruiting, Royal Marsden NHS Foundation Trust
New trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • PGR negative
|
Signatera™
25d
Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes. (PubMed, Breast Cancer Res Treat)
Taken together, our data provide clues to the important role of menin in ERα regulation and the formation of breast cancer subtypes.
Journal
|
ER (Estrogen receptor) • FOXA1 (Forkhead Box A1) • GATA3 (GATA binding protein 3) • MEN1 (Menin 1)
|
ER positive • ER negative
26d
Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. (PubMed, NPJ Breast Cancer)
Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.
Journal • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HR negative • HR negative + HER-2 positive
29d
A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape. (PubMed, J Transl Med)
Overall, this study revealed five heterogeneous immune subtypes among ER+/PR-/HER2- breast cancer, also provided important implications for clinical translations.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
ER positive • HER-2 negative • ER positive + PGR negative + HER-2 negative • PGR negative
29d
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma (clinicaltrials.gov)
P2, N=19, Completed, University of Utah | Recruiting --> Completed | Trial completion date: Jun 2023 --> Aug 2021 | Trial primary completion date: Jun 2022 --> Aug 2021
Trial completion • Trial completion date • Trial primary completion date
|
ER (Estrogen receptor)
|
ER positive • ER negative
1m
Clinical • Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CASP3 (Caspase 3)
|
TP53 mutation • HER-2 negative
|
carboplatin • paclitaxel • pegylated liposomal doxorubicin • epirubicin
1m
CXCL9 Is a Potential Biomarker of Immune Infiltration Associated With Favorable Prognosis in ER-Negative Breast Cancer. (PubMed, Front Oncol)
Finally, we performed immunohistochemistry with breast cancer tissue samples and observed that CXCL9 is highly expressed in the ER-negative subgroup and positively correlated with the immune-related factors LAG3, PD1, PDL1 and CTLA4 to varying degrees. These findings suggest that CXCL9 is an underlying biomarker for predicting the status of immune infiltration in ER-negative breast cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • GZMB (Granzyme B)
|
ER negative
1m
High BTBD7 expression positive is correlated with SLUG-predicted poor prognosis in hormone receptor-negative breast cancer. (PubMed, Ann Transl Med)
BTBD7 silencing inhibited EMT through regulation of SLUG expression. BTBD7 might act as a potential molecular target for gene therapy in HRNBC patients.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • CDH1 (Cadherin 1) • SNAI2 (Snail Family Transcriptional Repressor 2) • BTBD7 (BTB Domain Containing 7)
|
HER-2 overexpression • HR negative
1m
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 (clinicaltrials.gov)
P1, N=219, Active, not recruiting, Infinity Pharmaceuticals, Inc. | Trial completion date: Jun 2021 --> Oct 2022 | Trial primary completion date: Jun 2021 --> Oct 2021
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR • ER negative • PGR negative
|
Opdivo (nivolumab) • eganelisib (IPI-549)
1m
Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. (PubMed, JCI Insight)
Adrenal-permissive genotype is associated with estrogen-driven postmenopausal breast cancer. These findings link genetic inheritance of endogenous estrogen exposure to estrogen-driven breast cancer.
Journal
|
ER (Estrogen receptor) • HSD3B1 (Hydroxy-Delta-5-Steroid Dehydrogenase 3 Beta- And Steroid Delta-Isomerase 1)
|
ER positive • ER negative
1m
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
P1, N=45, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
Clinical • Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
|
UAB30
1m
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) (clinicaltrials.gov)
P2, N=40, Suspended, Dana-Farber Cancer Institute | Trial completion date: Apr 2024 --> Dec 2025 | Trial primary completion date: Apr 2022 --> Dec 2023
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Tecentriq (atezolizumab) • Trodelvy (sacituzumab govitecan-hziy)
1m
Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region. (PubMed, J Natl Cancer Inst)
Decreasing ER-negative breast cancer incidence differs meaningfully by US region and age among NHB and HW women. Analytical studies including minority women from higher and lower incidence areas may provide insights into breast cancer racial disparities.
Journal
|
ER (Estrogen receptor)
|
ER negative
1m
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. (PubMed, NPJ Breast Cancer)
Multivariable analysis adjusted for tumor characteristics suggested that rs57025206 was an independent survival marker. In addition, our exploratory analyses suggest that the associations between genetic variants and breast cancer patient survival may depend on tumor biological subgroup and clinical patient characteristics.
Clinical • Journal • BRCA Biomarker
|
ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
ER negative
1m
Dietary Vitamin A and Breast Cancer Risk in Black Women: The African American Breast Cancer Epidemiology and Risk (AMBER) Consortium. (PubMed, J Nutr)
Our findings on dietary vitamin A and breast cancer risks in Black women are consistent with observations in women of European descent and advance the literature showing an inverse association for ER-positive disease.
Clinical • Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
1m
Racial/ethnic differences in postmenopausal breast cancer risk by hormone receptor status: the Multiethnic Cohort Study. (PubMed, Int J Cancer)
Our study shows that associations of OC use and obesity with ER+ and ER- breast cancer risk differ by race/ethnicity, but established risk factors do not fully explain racial/ethnic differences in risk. Further studies are needed to identify factors to explain observed racial/ethnic differences in breast cancer incidence.
Journal
|
ER (Estrogen receptor)
|
HR positive • ER positive
2ms
A-Brave: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (clinicaltrials.gov)
P3, N=474, Active, not recruiting, Istituto Oncologico Veneto IRCCS | Trial primary completion date: Jun 2021 --> Dec 2021
Clinical • Trial primary completion date • IO Companion diagnostic • PD(L)-1 companion diagnostic
|
HER-2 (Human epidermal growth factor receptor 2)
|
PD-L1 expression • HER-2 amplification • HER-2 negative • HR negative
|
Bavencio (avelumab)
2ms
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
tamoxifen • letrozole • zanidatamab (ZW25)
2ms
gp130 cytokines activate novel signaling pathways and alter bone dissemination in ER+ breast cancer cells. (PubMed, J Bone Miner Res)
In breast cancer patients, downregulation of the cytokines or receptors was associated with reduced relapse-free survival, but OSM was significantly elevated in patients with invasive disease and distant metastasis. Together these data indicate that the gp130 cytokines induce multiple signaling cascades in breast cancer cells, with a potential pro-tumorigenic role for OSM and pro-dormancy role for CNTF.
Journal
|
ER (Estrogen receptor) • IL6 (Interleukin 6) • LIFR (LIF Receptor Subunit Alpha)
|
ER positive • ER negative
2ms
Naturally occurring Girinimbine alkaloid inhibits the proliferation, migration, and invasion of human breast cancer cells via induction of apoptosis and inhibition of MEK/ERK and STAT3 signalling pathways. (PubMed, Acta Biochim Pol)
The anticancer effects of girinimbine were shown to be mediated via inhibition of the MEK/ERK as well as STAT3 signalling pathways. In conclusion, it may be proposed that girinimbine could be a promising anticancer agent against breast cancer, provided further in-depth studies are carried out.
Journal
|
ER (Estrogen receptor)
|
ER negative
2ms
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer (clinicaltrials.gov)
P2, N=40, Recruiting, University of Illinois at Chicago | Initiation date: Jul 2021 --> Oct 2021
Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • PGR negative
|
MammaPrint • EndoPredict®
|
azacitidine
2ms
I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov)
P2, N=4000, Recruiting, QuantumLeap Healthcare Collaborative | Trial completion date: Dec 2026 --> Dec 2031 | Trial primary completion date: Dec 2025 --> Dec 2030
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
|
TargetPrint®
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine) • Perjeta (pertuzumab) • doxorubicin hydrochloride • Verzenio (abemaciclib) • irinotecan • Talzenna (talazoparib) • veliparib (ABT-888) • MK-2206 • letrozole • Tukysa (tucatinib) • Jemperli (dostarlimab) • Libtayo (cemiplimab) • ganitumab (AMG479) • Turalio (pexidartinib) • amcenestrant (SAR439859) • ganetespib (ADX-1612) • trastuzumab duocarmazine (SYD985) • metformin • Cosela (trilaciclib) • Oraxol (oral paclitaxel/encequidar) • SD-101 • patritumab (U3-1287) • trebananib (AMG 386) • fianlimab (REGN3767) • ladiratuzumab vedotin (SGN-LIV1A)
2ms
Immunohistochemical and clinicopathologic features of estrogen receptor-negative, progesterone receptor-positive, HER-2 negative breast carcinomas. (PubMed, Rev Assoc Med Bras (1992))
Estrogen receptor -/progesterone receptor +/tumors exhibit aggressive behavior, similar to triple-negative tumors. An appropriate categorization of these tumors should be made to improve their therapeutic management.
Clinical • Journal
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TFF1 (Trefoil Factor 1)
|
HER-2 negative • ER negative • PGR positive
2ms
Abstract PS6-55: The prognostic utility of AR/ER ratio in young women with breast cancer. (PubMed, Cancer Res)
Our results suggest androgenic influences on clinical progression of breast cancer in this age group mediated through AR, has to be examined by its level in relation to the activity of ER, particularly in hormone receptor negative breast cancers. Even more importantly, examining these influences in the context of the menopausal status might help identify subgroups of patients most likely to benefit from interventions targeted at AR.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor)
|
HR positive • ER positive • ER negative • HR negative • AR expression
2ms
Clinical • Trial completion • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 negative • PGR positive • PGR negative
|
Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
2ms
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted (clinicaltrials.gov)
P1, N=6, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jul 2021 --> Jul 2022
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Imlygic (talimogene laherparepvec)
2ms
A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=320, Recruiting, Cyteir Therapeutics, Inc. | Trial completion date: Oct 2021 --> Oct 2022
Clinical • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative
|
Rituxan (rituximab) • gemcitabine • bendamustine • CYT-0851
2ms
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (clinicaltrials.gov)
P2, N=50, Active, not recruiting, Duke University | Trial completion date: Aug 2021 --> Jun 2022
Clinical • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR expression • PGR negative
|
Lynparza (olaparib) • Imfinzi (durvalumab)
2ms
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy (clinicaltrials.gov)
P=N/A, N=98, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2021 --> Aug 2022
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • ER negative • PGR positive • PGR negative
2ms
Myosteatosis at diagnosis is adversely associated with 2-year survival in women with estrogen receptor-negative metastatic breast cancer. (PubMed, Breast Cancer Res Treat)
Targeted interventions initiated within the first year of diagnosis to preserve or improve SM quality seem warranted for women with ER-MBC.
Clinical • Journal
|
ER (Estrogen receptor)
|
ER negative
2ms
Sesamol Epigenetically Induces Estrogen Receptor α Re-expression by Upregulating miR-370-3p in Estrogen Receptor α-Negative Breast Cancer. (PubMed, J Agric Food Chem)
Moreover, it endowed responsiveness of ERα-negative breast carcinoma to the endocrine treatment drug 4-hydroxytamoxifen without influencing the viability of normal human umbilical vein endothelial cells...In mice, sesamol significantly induced ERα re-expression via miR-370-3p-mediated downregulation of DNMT3A and DNMT3B. Sesamol may be a safe and effective option for clinical adjuvant therapy in patients with ERα-negative breast cancer.
Journal
|
ER (Estrogen receptor) • DNMT3A (DNA methyltransferase 1) • DNMT1 (DNA methyltransferase 1) • DNMT3B (DNA Methyltransferase 3 Beta) • MIR370 (MicroRNA 370)
|
ER expression
|
tamoxifen
2ms
Effect of Estrogen on Heteronemin-Induced Anti-proliferative Effect in Breast Cancer Cells With Different Estrogen Receptor Status. (PubMed, Front Cell Dev Biol)
In conclusion, Heteronemin suppressed both ER-positive and ER-negative breast cancer cell proliferation. Interactions between E and heteronemin in signal transduction, gene expressions, and biological activities provide insights into the complex pathways by which anti-proliferation is induced by heteronemin in E-replete environments.
Journal • IO biomarker
|
ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • STAT3 (Signal Transducer And Activator Of Transcription 3)
|
ER positive • ER negative • BCL2/BAX ratio elevation
2ms
Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer (clinicaltrials.gov)
P1, N=100, Active, not recruiting, Fred Hutchinson Cancer Research Center | Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2021 --> May 2022
Clinical • Enrollment closed • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
capecitabine • cyclophosphamide oral • methotrexate • cyclophosphamide intravenous
2ms
RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells. (PubMed, Oncogene)
RAC1 activity is important for RNA Pol II function at both promoters and enhancers of ER target genes and ER-regulated gene transcription is blocked by EHT 1864, in a dose-dependent manner. Having identified that RAC1 is an essential ER cofactor for ER protein stability and ER transcriptional activity, we report that RAC1 inhibition could be an effective therapeutic approach for ER-positive BC.
Journal
|
ER (Estrogen receptor) • RAC1 (Rac Family Small GTPase 1)
|
ER positive • ER negative • ER expression
2ms
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 negative • ER negative • PGR negative
|
Tecentriq (atezolizumab) • uliledlimab (TJD5)
2ms
Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals. (PubMed, HGG Adv)
For each signal, we conducted cross-cancer fine-mapping to prioritize the most plausible causal variants. Our findings provide a more in-depth understanding of the shared inherited basis across human cancers and expand our knowledge of the 5p15.33 region in carcinogenesis.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
3ms
[VIRTUAL] A Nomogram for Predicting the Subgroups of ER Low Positive Breast Cancer Based on Clinicopathological Characteristics (ECP 2021)
Based on clinicopathological characteristics, we have devel- oped and verified a nomogram that predicts the expression status of ER in patients with invasive breast cancer. It can be used to identify patients with ER low positive whose clinicopathological characteristics are similar to ER-negative patients and will help guide individualized and precise treatment of ER low positive breast cancer patients.
Clinical
|
ER (Estrogen receptor)
|
ER positive • ER negative
3ms
PALAVY: Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (clinicaltrials.gov)
P2, N=96, Recruiting, Abramson Cancer Center of the University of Pennsylvania | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR positive
|
Ibrance (palbociclib) • Bavencio (avelumab) • hydroxychloroquine
3ms
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. (PubMed, J Clin Oncol)
Patients with triple-negative, programmed cell death ligand-1-positive MBC may be offered the addition of immune checkpoint inhibitor to chemotherapy as first-line therapy. Patients with triple-negative, programmed cell death ligand-1-negative MBC should be offered single-agent chemotherapy rather than combination chemotherapy as first-line treatment, although combination regimens may be offered for life-threatening disease. Patients with triple-negative MBC who have received at least two prior therapies for MBC should be offered treatment with sacituzumab govitecan. Patients with triple-negative MBC with germline BRCA mutations previously treated with chemotherapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy. Patients with HR-positive human epidermal growth factor receptor 2-negative MBC for whom chemotherapy is being considered should be offered single-agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease. Patients with HR-positive MBC with disease progression on an endocrine agent may be offered treatment with either endocrine therapy with or without targeted therapy or single-agent chemotherapy. Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy. No recommendation regarding when a patient's care should be transitioned to hospice or best supportive care alone is possible.Additional information is available at www.asco.org/breast-cancer-guidelines.
Clinical • Journal • BRCA Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset)
|
HR positive • HER-2 negative • PD-L1 negative • HR negative • BRCA mutation
|
Trodelvy (sacituzumab govitecan-hziy)
3ms
Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer (clinicaltrials.gov)
P1b, N=22, Active, not recruiting, Barbara Parker, MD | Recruiting --> Active, not recruiting | N=15 --> 22 | Trial completion date: Jun 2021 --> Jan 2022
Clinical • Enrollment closed • Enrollment change • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD133 • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • ROR1 expression • PGR negative
|
paclitaxel • cirmtuzumab (UC-961)
3ms
A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov)
P2, N=46, Active, not recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting --> Active, not recruiting
Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PD-1 (Programmed cell death 1)
|
HER-2 negative • ER negative • PGR negative
|
AiTan (rivoceranib) • AiRuiKa (camrelizumab) • Halaven (eribulin mesylate)
3ms
Healthful and unhealthful plant-based diets and risk of breast cancer in U.S. women: results from the Nurses' Health Studies. (PubMed, Cancer Epidemiol Biomarkers Prev)
Conclusions This study provides evidence that adherence to a healthful plant-based diet may reduce the risk of breast cancer, especially those that are more likely to be aggressive tumors. Impact This is the first prospective study investigating the relation between healthful and unhealthful plant-based dietary indices and risk of total and subtype-specific breast cancer.
Clinical • Journal
|
ER (Estrogen receptor)
|
ER negative
3ms
Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. (PubMed, J Clin Oncol)
This study suggests that all women diagnosed with triple-negative breast cancer or ER-negative breast cancer should receive genetic testing and that women over age 65 years with BRCA1 and BRCA2 PVs and perhaps with PALB2 and CHEK2 PVs should be considered for magnetic resonance imaging screening.
Clinical • Journal • BRCA Biomarker
|
ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2)
|
ER positive • ER negative
3ms
[VIRTUAL] Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA (ESMO 2021)
Patients are randomized 1:1 to receive either SG 10 mg/kg body weight (days 1, 8 q3w for eight cycles) or treatment of physician´s choice (capecitabine 2000 mg/m2 day 1-14 q21 or platinum-based chemotherapy i.e. carboplatin AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles or observation). Secondary endpoints include overall survival (OS, key secondary endpoint), distant DFS, locoregional recurrence-free interval, safety, compliance, patient reported outcome, and quality of life. As of 29th April 2021, 33/1200 patients have been randomized in Germany.
Clinical • P3 data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
carboplatin • capecitabine • Trodelvy (sacituzumab govitecan-hziy)
3ms
[VIRTUAL] Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: A meta-analysis of randomised trials (ESMO 2021)
Patients received either T and L or T alone, in combination with paclitaxel or anthracyclines. These findings further validate the role of pCR as a strong predictor of outcome in patients with HER2+, especially in hormone receptor-negative disease. Moreover, we here provide robust evidence that dual blockade with L in combination with T and chemotherapy prolongs overall survival, suggesting that L could be repurposed in early settings.
Retrospective data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HR negative
|
Herceptin (trastuzumab) • paclitaxel • lapatinib
3ms
Deletion of Foxa1 in the mouse mammary gland results in abnormal accumulation of luminal progenitor cells: a link between reproductive factors and ER-/TNBC breast cancer? (PubMed, Am J Cancer Res)
Consistent with this hypothesis, we show that deletion of Foxa1 in the mouse mammary gland results in a two-fold increase in the proportion of luminal progenitor cells and a reduction in mammary gland epithelial cells that stain positive for ER. These results provide compelling support for the notion that reduced Foxa1 expression is sufficient to alter mammary gland luminal cell fate determination in vivo, which could be a mechanism linking parity with ER- breast cancer.
Preclinical • Journal
|
ER (Estrogen receptor) • FOXA1 (Forkhead Box A1)
|
ER negative
3ms
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer (clinicaltrials.gov)
P1b/2, N=72, Recruiting, Hutchison Medipharma Limited | Not yet recruiting --> Recruiting
Clinical • Enrollment open • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 negative • ER negative • PGR negative
|
Baize’an (tislelizumab) • Elunate (fruquintinib)
3ms
Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. (PubMed, J Immunother Cancer)
Together, these findings demonstrate a novel effect of ER targeting drugs on the interaction of ER+ and, surprisingly, ER- tumors cells with the immune system. This study is the first to demonstrate the potential use of ER targeting drugs as immunomodulatory agents in an ER agnostic manner and may inform novel immunotherapy strategies in breast cancer.
Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative
|
tamoxifen • fulvestrant • Anktiva (inbakicept)
3ms
Serum iron status and the risk of breast cancer in the European population: a two-sample Mendelian randomisation study. (PubMed, Genes Nutr)
In our MR study, the liberal approach suggested that changes in the concentration of transferrin could increase the risk of ER-negative breast cancer, although the levels of other iron status markers had no effect on the risk of breast cancer or its subtypes. This should be verified in future studies.
Clinical • Journal
|
ER (Estrogen receptor)
|
ER negative
4ms
[VIRTUAL] Outcome of breast cancer with weak positive hormone receptors: a population related analysis of a 15-year collective (GSS 2021)
Within the HER2-positive cohort (n = 5194), however, there were no statistically significant differences between the three HR groups. Summary The current threshold value for hormone receptor positivity and its clinical relevance should The systemic therapy of weak HR-positive / HER2-negative tumors could be based on the therapy of triple-negative tumors.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative
4ms
Acid-base transporters and pH dynamics in human breast carcinomas predict proliferative activity, metastasis, and survival. (PubMed, Elife)
We conclude that the molecular mechanisms of acid-base regulation depend on clinicopathological characteristics of breast cancer patients. NBCn1 expression and dependency on Na,HCO-cotransport for pH regulation, measured in biopsies of human primary breast carcinomas, independently predict proliferative activity, lymph node metastasis, and patient survival.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER negative
4ms
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 negative • HR negative
|
carboplatin • Tecentriq (atezolizumab) • paclitaxel
4ms
Differential Expression of BOC, SPOCK2, and GJD3 Is Associated with Brain Metastasis of ER-Negative Breast Cancers. (PubMed, Cancers (Basel))
The overexpression of BOC, SPOCK2, and GJD3 is associated with the invasion of breast cancer into the brain. Further studies to determine their specific function and potential value as brain metastasis biomarkers are required.
Journal
|
ER (Estrogen receptor)
|
ER negative
4ms
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IGFBP2 (Insulin-like growth factor binding protein 2) • IL10 (Interleukin 10) • CD4 (CD4 Molecule)
|
ER negative • PGR negative
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
4ms
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones (clinicaltrials.gov)
P2, N=70, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • ER positive • HER-2 negative • ER negative • PGR negative
|
paclitaxel • Xofigo (radium Ra-223 dichloride)
4ms
RPOS+2: Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer (clinicaltrials.gov)
P=N/A, N=40, Recruiting, Centre Antoine Lacassagne | Initiation date: May 2021 --> Sep 2021
Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
4ms
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores. (PubMed, BMC Med Res Methodol)
In conclusion, this study indicated in ER+/HER2- breast cancers the various status of PR expression can be an indication of molecular variation, particularly for the growth factor pathway activation.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IGF1 (Insulin-like growth factor 1)
|
ER positive • HER-2 negative • PGR negative
4ms
The clinical and molecular significance associated with STING signaling in breast cancer. (PubMed, NPJ Breast Cancer)
Importantly, a gene signature defining low pnSTING expression is predictive of poor prognosis in independent ER+ datasets. Low pnSTING is associated with chromosomal instability, MYC amplification and mTOR signaling, suggesting novel therapeutic approaches for this subgroup.
Clinical • Journal • IO biomarker
|
ER (Estrogen receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
ER positive • MYC amplification • mTOR amplification
4ms
Bicalutamide in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=28, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed | Trial completion date: Mar 2022 --> Jun 2021 | Trial primary completion date: Mar 2022 --> Jun 2021
Clinical • Trial completion • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
AR positive • PGR negative
|
bicalutamide
4ms
CISPLATIN + AZD-1775 In Breast Cancer (clinicaltrials.gov)
P2, N=37, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Sep 2021 --> Nov 2020
Trial completion • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
cisplatin • adavosertib (AZD1775)
4ms
Clinical • Enrollment change • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
|
HER-2 amplification • PIK3CA mutation • HER-2 negative • PTEN mutation • PIK3CA expression
|
Halaven (eribulin mesylate) • Aliqopa (copanlisib)
4ms
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Jun 2021 --> Sep 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative
|
methotrexate IV
4ms
Clinical • Enrollment open • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)
|
HR positive • HER-2 negative
4ms
Landscape of Toll-like receptors expression in tumor microenvironment of Triple Negative Breast Cancer (TNBC): distinct roles of TLR4 and TLR8. (PubMed, Gene)
TLR4 expression in chemoresponsive TNBC was also validated in TNBC cell lines upon Paclitaxel (PTX) treatment. Collectively, the present study identified specific DETs in TNBC and discovered a prospective role of TLR4 and TLR8 in the maintenance of tumor-immune-microenvironment.
Journal • IO biomarker
|
TLR4 (Toll Like Receptor 4) • TLR8 (Toll Like Receptor 8) • TLR3 (Toll Like Receptor 3)
|
HR negative
|
paclitaxel
4ms
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer (clinicaltrials.gov)
P2, N=45, Active, not recruiting, Mayo Clinic | Suspended --> Active, not recruiting | N=96 --> 45
Clinical • Enrollment closed • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AURKA (Aurora kinase A) • CD44 • CD24 (CD24 Molecule) • SOX2
|
HER-2 amplification • ER positive • HER-2 negative • HER-2 expression • ER negative • CD44 expression
|
fulvestrant • alisertib (MLN8237)
4ms
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
mitoxantrone liposomal (PLM60)
4ms
Clinical • Phase classification • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Keytruda (pembrolizumab) • Zejula (niraparib)
4ms
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 amplification • ER negative • PGR negative
|
Herceptin (trastuzumab) • capecitabine • vinorelbine tartrate
5ms
Clinical • Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER negative • PGR negative
|
Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
5ms
Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer. (PubMed, Am J Cancer Res)
Prevention of estrogen receptor-negative (ER-) breast cancer is an unmet challenge, although tamoxifen and aromatase inhibitors can successfully decrease the incidence of ER-positive (ER+) breast cancer...Both genetic knockdown of PIK3CA or intervention with low-doses of a PI3K inhibitor (GDC-0941) prevented the dysplasia phenotype of semi-transformed human ER- mammary epithelial cells in 3-dimensional culture in vitro...In human ER- breast cancer, PI3K activation is correlated with significantly reduced CCL5, CXCL10 and CD8A expression, suggesting that the decreased CD8 T-cell recruitment and escape of immune surveillance may contribute to ER- breast cancer development. In summary, our study indicates that low-dose PI3K inhibitor treatment may intervene early stage ER- breast cancer development by enhancing immune surveillance via CCL5/CXCL10.
Journal
|
ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • GZMB (Granzyme B)
|
ER positive • ER negative
|
tamoxifen • pictilisib (GDC-0941)
5ms
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=0, Withdrawn, Thomas Jefferson University | N=42 --> 0 | Not yet recruiting --> Withdrawn
Clinical • Enrollment change • Trial withdrawal • Combination therapy • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PD-L2 (Programmed Cell Death 1 Ligand 2) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative
|
Keytruda (pembrolizumab) • Bria-IMT (SV-BR-1-GM) • cyclophosphamide intravenous
5ms
Clinical • New P2 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Halaven (eribulin mesylate) • Baize’an (tislelizumab)
5ms
LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer (clinicaltrials.gov)
P1, N=0, Withdrawn, Antoinette Tan, MD | N=96 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 negative • HR negative
|
carboplatin • paclitaxel • doxorubicin hydrochloride • Zejula (niraparib) • Neulasta (pegfilgrastim) • cyclophosphamide intravenous
5ms
Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm? (PubMed, Cancers (Basel))
Concluding, the assumption that TNBC is completely hormone-insensitive is incorrect. However, the direction of the effects of the alternative pathways is not always clear, and will need to be investigated further.
Review • Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
AR expression • ER expression
5ms
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR negative
5ms
Clinical • Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
docetaxel • Neulasta (pegfilgrastim) • amlodipine besilate • aspirin
5ms
Sitravatinib in Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=30, Recruiting, Maryam Nemati Shafaee | Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2023 --> Feb 2024
Enrollment open • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTPN12 (Protein Tyrosine Phosphatase Non-Receptor Type 12)
|
sitravatinib (MGCD516)
5ms
CISPLATIN + AZD-1775 In Breast Cancer (clinicaltrials.gov)
P2, N=37, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2024 --> Sep 2021
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
cisplatin • adavosertib (AZD1775)
5ms
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer (clinicaltrials.gov)
P1, N=30, Not yet recruiting, George T. Budd | Trial completion date: Dec 2021 --> Sep 2022 | Initiation date: Mar 2021 --> Jul 2021 | Trial primary completion date: Oct 2021 --> Jul 2022
Clinical • Trial completion date • Trial initiation date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
|
HER-2 negative • ER negative • PGR negative
|
alpha-lactalbumin vaccine
5ms
[VIRTUAL] PI3K/AKT pathway is involved in fenhexamid-induced migration and angiogenesis in breast cancer cells via an ER-dependent manner (EACR 2021)
Material and Methods ER positive MCF-7 and ER negative MDA-MB-231 breast cancer cells were exposed to 17β-estradiol (E2, 10-9 M), Fen (10-5 M and 10-7 M), ICI 182,780 (ICI; an ER antagonist, 10-8 M) or/and Pictilisib (Pic; a PI3K inhibitor, 10-7 M), and subsequently subjected to migration assay, live cell motility monitoring, trans-chamber assay, immunofluorescence, angiogenesis assay, tumor spheroid formation, and Western blot analysis...Conclusion Taken together, these results indicate that Fen as well as E2 promote the growth of breast cancer cells via the ER or/and PI3K pathways. Although a relatively safe pesticide, Fen may therefore play a role as an endocrine disrupting chemical in ER-positive breast cancer cells via the ER and PI3K signaling pathways.
ER (Estrogen receptor) • CDH1 (Cadherin 1) • SOX2 • VIM (Vimentin)
|
ER positive • ER negative • VEGFA expression • VIM expression
|
pictilisib (GDC-0941)
5ms
[VIRTUAL] PI3K/AKT pathway is involved in fenhexamid-induced migration and angiogenesis in breast cancer cells via an ER-dependent manner (EACR 2021)
Material and Methods ER positive MCF-7 and ER negative MDA-MB-231 breast cancer cells were exposed to 17β-estradiol (E2, 10-9 M), Fen (10-5 M and 10-7 M), ICI 182,780 (ICI; an ER antagonist, 10-8 M) or/and Pictilisib (Pic; a PI3K inhibitor, 10-7 M), and subsequently subjected to migration assay, live cell motility monitoring, trans-chamber assay, immunofluorescence, angiogenesis assay, tumor spheroid formation, and Western blot analysis...Conclusion Taken together, these results indicate that Fen as well as E2 promote the growth of breast cancer cells via the ER or/and PI3K pathways. Although a relatively safe pesticide, Fen may therefore play a role as an endocrine disrupting chemical in ER-positive breast cancer cells via the ER and PI3K signaling pathways.
ER (Estrogen receptor) • CDH1 (Cadherin 1) • SOX2 • VIM (Vimentin)
|
ER positive • ER negative • VEGFA expression • VIM expression
|
pictilisib (GDC-0941)
5ms
[VIRTUAL] PI3K/AKT pathway is involved in fenhexamid-induced migration and angiogenesis in breast cancer cells via an ER-dependent manner (EACR 2021)
Material and Methods ER positive MCF-7 and ER negative MDA-MB-231 breast cancer cells were exposed to 17β-estradiol (E2, 10-9 M), Fen (10-5 M and 10-7 M), ICI 182,780 (ICI; an ER antagonist, 10-8 M) or/and Pictilisib (Pic; a PI3K inhibitor, 10-7 M), and subsequently subjected to migration assay, live cell motility monitoring, trans-chamber assay, immunofluorescence, angiogenesis assay, tumor spheroid formation, and Western blot analysis...Conclusion Taken together, these results indicate that Fen as well as E2 promote the growth of breast cancer cells via the ER or/and PI3K pathways. Although a relatively safe pesticide, Fen may therefore play a role as an endocrine disrupting chemical in ER-positive breast cancer cells via the ER and PI3K signaling pathways.
ER (Estrogen receptor) • CDH1 (Cadherin 1) • SOX2 • VIM (Vimentin)
|
ER positive • ER negative • VEGFA expression • VIM expression
|
pictilisib (GDC-0941)
5ms
[VIRTUAL] PI3K/AKT pathway is involved in fenhexamid-induced migration and angiogenesis in breast cancer cells via an ER-dependent manner (EACR 2021)
Material and Methods ER positive MCF-7 and ER negative MDA-MB-231 breast cancer cells were exposed to 17β-estradiol (E2, 10-9 M), Fen (10-5 M and 10-7 M), ICI 182,780 (ICI; an ER antagonist, 10-8 M) or/and Pictilisib (Pic; a PI3K inhibitor, 10-7 M), and subsequently subjected to migration assay, live cell motility monitoring, trans-chamber assay, immunofluorescence, angiogenesis assay, tumor spheroid formation, and Western blot analysis...Conclusion Taken together, these results indicate that Fen as well as E2 promote the growth of breast cancer cells via the ER or/and PI3K pathways. Although a relatively safe pesticide, Fen may therefore play a role as an endocrine disrupting chemical in ER-positive breast cancer cells via the ER and PI3K signaling pathways.
ER (Estrogen receptor) • CDH1 (Cadherin 1) • SOX2 • VIM (Vimentin)
|
ER positive • ER negative • VEGFA expression • VIM expression
|
pictilisib (GDC-0941)
5ms
[VIRTUAL] A role for the glycerophosphodiesterase EDI3 in HER2 positive breast cancer (EACR 2021)
Silencing EDI3 with siRNA decreased cell viability and sensitized cells to lapatinib and trastuzumab. Finally, pharmacological inhibition and siRNA silencing of HER2 led to decreased EDI3 expression, and proteins downstream of HER2 signaling, namely mTOR and GSK3b, may be involved in regulating EDI3 expression. Conclusion Investigating EDI3 in HER2+/ER- breast cancer may lead to a better understanding of choline metabolism in this specific cancer subtype, and thus provide potential targets for treatment.
HER-2 (Human epidermal growth factor receptor 2) • mTOR (Mechanistic target of rapamycin kinase) • GSK3B (Glycogen Synthase Kinase 3 Beta)
|
HER-2 positive • HER-2 expression
|
Herceptin (trastuzumab) • lapatinib
5ms
[VIRTUAL] A role for the glycerophosphodiesterase EDI3 in HER2 positive breast cancer (EACR 2021)
Silencing EDI3 with siRNA decreased cell viability and sensitized cells to lapatinib and trastuzumab. Finally, pharmacological inhibition and siRNA silencing of HER2 led to decreased EDI3 expression, and proteins downstream of HER2 signaling, namely mTOR and GSK3b, may be involved in regulating EDI3 expression. Conclusion Investigating EDI3 in HER2+/ER- breast cancer may lead to a better understanding of choline metabolism in this specific cancer subtype, and thus provide potential targets for treatment.
HER-2 (Human epidermal growth factor receptor 2) • mTOR (Mechanistic target of rapamycin kinase) • GSK3B (Glycogen Synthase Kinase 3 Beta)
|
HER-2 positive • HER-2 expression
|
Herceptin (trastuzumab) • lapatinib
5ms
[VIRTUAL] A role for the glycerophosphodiesterase EDI3 in HER2 positive breast cancer (EACR 2021)
Silencing EDI3 with siRNA decreased cell viability and sensitized cells to lapatinib and trastuzumab. Finally, pharmacological inhibition and siRNA silencing of HER2 led to decreased EDI3 expression, and proteins downstream of HER2 signaling, namely mTOR and GSK3b, may be involved in regulating EDI3 expression. Conclusion Investigating EDI3 in HER2+/ER- breast cancer may lead to a better understanding of choline metabolism in this specific cancer subtype, and thus provide potential targets for treatment.
HER-2 (Human epidermal growth factor receptor 2) • mTOR (Mechanistic target of rapamycin kinase) • GSK3B (Glycogen Synthase Kinase 3 Beta)
|
HER-2 positive • HER-2 expression
|
Herceptin (trastuzumab) • lapatinib
5ms
[VIRTUAL] A role for the glycerophosphodiesterase EDI3 in HER2 positive breast cancer (EACR 2021)
Silencing EDI3 with siRNA decreased cell viability and sensitized cells to lapatinib and trastuzumab. Finally, pharmacological inhibition and siRNA silencing of HER2 led to decreased EDI3 expression, and proteins downstream of HER2 signaling, namely mTOR and GSK3b, may be involved in regulating EDI3 expression. Conclusion Investigating EDI3 in HER2+/ER- breast cancer may lead to a better understanding of choline metabolism in this specific cancer subtype, and thus provide potential targets for treatment.
HER-2 (Human epidermal growth factor receptor 2) • mTOR (Mechanistic target of rapamycin kinase) • GSK3B (Glycogen Synthase Kinase 3 Beta)
|
HER-2 positive • HER-2 expression
|
Herceptin (trastuzumab) • lapatinib
5ms
RPOS+2: Per-Operative Radiotherapy by Papillon +TM in Localized Breast Cancer (clinicaltrials.gov)
P=N/A, N=40, Recruiting, Centre Antoine Lacassagne | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
5ms
The risk of contralateral breast cancer: a SEER-based analysis. (PubMed, Br J Cancer)
Women with unilateral breast cancer experience an annual risk of contralateral breast cancer ~0.4% per year, which persists over the 25-year follow-up period.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
5ms
Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. (PubMed, JAMA Oncol)
The findings suggest that there is not sufficient evidence to make policy changes related to genetic testing based on race alone. Instead, all efforts should be made to ensure equal access to and uptake of genetic testing to minimize disparities in care and outcomes.
Clinical • Journal • BRCA Biomarker
|
ER (Estrogen receptor) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2)
|
ER negative
5ms
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer (clinicaltrials.gov)
P2, N=51, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative
|
Avastin (bevacizumab) • cisplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide intravenous • progesterone
5ms
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • PGR negative
|
EndoPredict®
|
azacitidine
5ms
Peri-Operative Ipilimumab+Nivolumab and Cryoablation in Women With Triple-negative Breast Cancer (clinicaltrials.gov)
P2, N=80, Recruiting, Cedars-Sinai Medical Center | Trial completion date: May 2023 --> Jun 2024 | Trial primary completion date: May 2021 --> Jun 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
5ms
Multiplexed digital spatial profiling of invasive breast tumors from Black and White women. (PubMed, Mol Oncol)
DSP immune analytes were inversely associated with ER expression, in agreement with a substantial body of previous work that documents higher immune infiltration in ER-negative breast cancers. This technology revealed that scores of the B7-H3 protein were significantly lower in breast cancers from Black women compared with White women, an intriguing finding that requires replication in independent and racially diverse female populations.
Clinical • Journal
|
ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • IL7R (Interleukin 7 Receptor) • STING (stimulator of interferon response cGAMP interactor 1) • EPCAM (Epithelial cell adhesion molecule) • NCAM1 (Neural cell adhesion molecule 1)
|
ER positive • ER negative
5ms
Fruit and vegetable consumption and incident breast cancer: a systematic review and meta-analysis of prospective studies. (PubMed, Br J Cancer)
These findings suggest that high total fruit and vegetable consumption are associated with reduced risk of overall, postmenopausal, ER+/PR+ and ER-/PR- breast cancer.
Retrospective data • Review • Journal
|
PGR (Progesterone receptor)
|
PGR positive
5ms
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • PGR negative
|
EndoPredict®
|
azacitidine
5ms
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=184, Active, not recruiting, Daiichi Sankyo Co., Ltd. | Trial primary completion date: Feb 2021 --> Aug 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HR positive • HER-2 negative • HER-2 expression
|
patritumab deruxtecan (U3-1402)
5ms
IMpALA: A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer (clinicaltrials.gov)
P2, N=42, Not yet recruiting, The Christie NHS Foundation Trust | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Aug 2021 --> Aug 2022
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
HER-2 negative • PTGS2 expression
|
Bavencio (avelumab) • aspirin • lansoprazole
5ms
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
P1, N=45, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Jul 2021 --> Feb 2022
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
|
UAB30
5ms
Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer. (PubMed, Front Oncol)
The results suggest that CPT is a novel BCRP inhibitor via blocking the oligomer formation of BCRP on the cell membrane. CPT is able to inhibit the activity of BCRP in an ERα-dependent and -independent manner, sensitizing breast cancer cells to chemotherapy.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative • ER expression
5ms
[VIRTUAL] Metastasis to Ipsilateral Supraclavicular and Cervical Lymph Nodes in Breast Cancer: A Single Center 15-Year Experience (ASBrS 2021)
With improvements in systemic therapy leading to distant control, surgeons are asked to consider resection of advanced nodal disease for local disease control in breast cancer. This limited study highlights the importance of using NAST to define the tumor biology. Based on our institutional experience, it is reasonable to consider an aggressive approach to local-regional control for patients with a good response to NAST.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
5ms
[VIRTUAL] Presentation, Management, and Outcomes of Very Young Women with Breast Cancer (Age <30) Compared to Other Pre-Menopausal Women (ASBrS 2021)
Very young women with breast cancer were not more likely to have genetic mutations or familial breast cancer than older premenopausal women, but did have other significant differences in demographics, risk factors, and disease characteristics. They presented more often with late stage, highrisk disease, and had worse outcomes even after correcting for differences at presentation.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER negative
6ms
Dairy foods, calcium, and risk of breast cancer overall and for subtypes defined by estrogen receptor status: a pooled analysis of 21 cohort studies. (PubMed, Am J Clin Nutr)
Our study shows that adult dairy or calcium consumption is unlikely to associate with a higher risk of breast cancer and that higher yogurt and cottage/ricotta cheese intakes were inversely associated with the risk of ER-negative breast cancer, a less hormonally dependent subtype with poor prognosis. Future studies on fermented dairy products, earlier life exposures, ER-negative breast cancer, and different racial/ethnic populations may further elucidate the relation.
Retrospective data • Journal
|
ER (Estrogen receptor)
|
ER negative
6ms
Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer (clinicaltrials.gov)
P1, N=29, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Aug 2022 --> Apr 2023
Clinical • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • HER-2 expression • ER negative • PGR negative
|
paclitaxel • galunisertib (LY2157299)
6ms
New trial • Liquid biopsy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
6ms
Assessment of Candidate Protein Expression in Breast Cancer Specimens (clinicaltrials.gov)
P=N/A, N=80, Recruiting, Case Comprehensive Cancer Center | Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2021 --> Dec 2021
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER negative • PGR negative
6ms
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=100, Recruiting, Northwestern University | Trial completion date: Jul 2022 --> Jul 2023 | Trial primary completion date: Jun 2021 --> Jun 2022
Clinical • Trial completion date • Trial primary completion date • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • HER-2 negative
|
Keytruda (pembrolizumab) • carboplatin
6ms
[VIRTUAL] Trastuzumab-dkst versus trastuzumab: Real-world pCR rates in patients with HER2+ breast cancer treated with neoadjuvant chemotherapy plus trastuzumab from Alberta, Canada. (ASCO 2021)
pCR rates were similar for patients treated with trastuzumab-dkst compared to trastuzumab in our real world study of HER2+ neoadjuvant EBC and comparable to pivotal phase 3 trials . For a 65 kg patient, the estimated cost savings of trastuzumab-dkst therapy is $22,000, and approximately $240-300 for a non-anthracycline chemotherapy backbone.
Clinical • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • ER positive + PGR positive • PGR positive • PGR negative
|
Ogivri (trastuzumab biosimilar)
6ms
[VIRTUAL] Tumor infiltrating lymphocytes and programmed death ligand-1 can identify different prognostic profiles in breast cancer. (ASCO 2021)
In our cohort, PD-L1 positivity together with low TILs identified a subset of BC patients with a worse RFS . Interestingly, patients with HR+/HER2- BC fared worse in the low TILs/PD-L1+ subcategory than in the low TILs/PD-L1- group . Future studies are warranted to explore the prognostic value of categorizing patients based on TILs and PD-L1 status in different BC subtypes.
Tumor-Infiltrating Lymphocyte • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor)
|
HER-2 negative • ER negative
|
VENTANA PD-L1 (SP142) Assay
6ms
[VIRTUAL] Predictive factors associated with a pathologic complete response in a Mexican HER2+ breast cancer population. (ASCO 2021)
Background: The current standard of treatment for locally advanced and early HER2+ breast cancer is the use of neoadjuvant chemotherapy (NAC) in combination with trastuzumab and pertuzumab . In this Mexican population there is a significant difference between the percentage of patients who achieve pCR in relation to the status of hormone receptors, favoring those patients with hormone receptor negative tumors . Nevertheless, most of the population achieves this benefit regardless of their hormone status, as HER2+ tumors showed sensitivity to chemotherapy and to the humanized anti-HER2 therapies . No other clinical or pathological variables were associated with pCR.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 expression • HR negative
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
6ms
[VIRTUAL] Treatment and prognosis of advanced triple-negative breast cancer patients with HER2-low expression: A 15-year retrospective study. (ASCO 2021)
The most commonly used regimens for first- and second-line were combination chemotherapy, which were 74.7% and 65.3%, respectively; paclitaxel (55.6%) and platinum (43.8%) were the most commonly used drugs for the first-line treatment... Based on this observational cohort study, there is no significant difference in the current treatment patterns and prognosis between HER2-low pts and TN pts . However, with the emergence of HER2-targeted ADC therapy, HER2-low ABC pts which were commonly defined as TNBC may benefit from these novel therapies . The recurrence subgroup with DFI≥12 months presented a trend of longer OS, suggesting the therapy mode and response in early stage should be considered in advanced TNBC treatment.
Retrospective data • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression • HER-2 underexpression
|
paclitaxel
6ms
[VIRTUAL] Determination of endocrine sensitivity by response of the proliferative marker KI67 after short-term preoperative endocrine therapy and their correlation to oncotype score platform. (ASCO 2021)
All premenopausal patients received Tamoxifeno as preoperative ET and letrozole for postmenopausal . We have found an ES of 62% in the whole population with the following distribution according RS: 80% in RS 26 . Of note, in premenopausal patients, ES rate in RS > 26 is only of 33% . Determination of ES by response of ki67 is feasible and correlates with data of genomic platforms .
PGR (Progesterone receptor)
|
PGR negative
|
Oncotype DX Breast Recurrence Score®Test
|
tamoxifen • letrozole
6ms
[VIRTUAL] First-line treatment with a cyclin-dependent kinase 4/6 inhibitor combined with an aromatase inhibitor for hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: Population-based outcomes for patients treated in Alberta, Canada. (ASCO 2021)
Palbociclib was prescribed in 94% of patients and the remaining patients received ribociclib . The real-world outcomes of first-line use of CDK4/6i and AI are encouraging . PR negative tumors and dose reduction appear to be negative prognostic markers . CDK4/6i + AI as first-line treatment for HR-positive, HER2-negative MBC in Alberta is justified based on favorable PFS and early OS outcomes.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CDKN2C (Cyclin Dependent Kinase Inhibitor 2C)
|
HR positive • HER-2 negative • PGR negative
|
Ibrance (palbociclib) • Kisqali (ribociclib)
6ms
Surgical decisions in older women with early breast cancer: patient and disease factors. (PubMed, Br J Surg)
The reasons for the observer differences should be further explored to ensure consistency in treatment decisions.
Clinical • Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
6ms
[VIRTUAL] Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes. (ASCO 2021)
Differences in ER, PR, HER2 expression levels were observed in germline PV carrier breast cancers, signaling differential impacts by germline PVs on the tumor evolution process . It is likely that tumor differences in PV carriers influence responses to therapies, including hormone therapy, anti-HER2 therapy, and subsequent survival.
BRCA Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • PGR (Progesterone receptor) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • CDH1 (Cadherin 1)
|
HER-2 amplification • ER positive • HER-2 negative • HER-2 expression • ER negative • CDH1 expression • TP53 expression • ATM expression • BRCA2 expression
6ms
[VIRTUAL] Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer. (ASCO 2021)
The adrenal-permissive genotype is associated with estrogen-driven postmenopausal breast cancer . These findings link genetic inheritance of endogenous estrogen exposure to estrogen-driven breast cancer and have broad implications for risk stratification, prevention, potential biomarkers for hormonal therapy response and possibly other clinical outcomes related to estrogen physiology in postmenopausal women.
ER (Estrogen receptor) • HSD3B1 (Hydroxy-Delta-5-Steroid Dehydrogenase 3 Beta- And Steroid Delta-Isomerase 1)
|
ER positive • ER negative
6ms
[VIRTUAL] A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. (ASCO 2021)
EA1181 is a NAT de-escalation trial of a taxane, trastuzumab and pertuzumab (THP) in clinical stage II-III HER2+ EBC; pts with a pCR complete HP +/- adjuvant radiation (RT) +/- endocrine therapy (ET) . experimental arm 82% & 87%, HR = 0.7), with a two-sided alpha of 0.05 and power of 80% . The sample size is 981; target accrual = 1031 pts; activation and completion dates are 01/6/21 and ̃ 01/2028.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive
|
Kadcyla (ado-trastuzumab emtansine) • Perjeta (pertuzumab) • Tukysa (tucatinib)
6ms
[VIRTUAL] De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. (ASCO 2021)
For the first time, we have shown both excellent pCR and survival in patients treated by de-escalated neoadjuvant CT+P+T irrespective of further CT use in a prospective multicenter study . Investigation of CT-free regimens may need to be focussed on selected patients only (e.g . with high HER2 expression/non-basal-like tumors) .
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 expression • HER-2-H
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay • nCounter® Breast Cancer 360™ Panel
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
6ms
[VIRTUAL] Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. (ASCO 2021)
Patients are randomized 1:1 to receive either sacituzumab govitecan 10 mg/kg body weight (days 1, 8 q3w for eight cycles) or treatment of physician´s choice (capecitabine 2000 mg/m² day 1-14 q21 or platinum-based chemotherapy i.e . carboplatin AUC 5 q3w or AUC 1.5 weekly for eight 3 weekly cycles or observation)...As of February 2 2021, 7/1200 patients have been randomized in Germany . International study groups will join soon.
Clinical • P3 data
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
carboplatin • capecitabine • Trodelvy (sacituzumab govitecan-hziy)
6ms
[VIRTUAL] A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy (JCOG1806: AMATERAS-BC study). (ASCO 2021)
HER2 inhibitors (trastuzumab and pertuzumab) and cytotoxic drugs as PST are administered for all patients (pts) . Recent reports found that HR positive HER2(+) subtype has higher concordance between pCR and cCR by adding needle biopsy in the diagnosis, so we are planning to include HR positive subtype in this trial . This clinical trial has been registered at Japan Registry of Clinical Trials as jRCTs031190129 and conducted by the Japan Clinical Oncology Group (JCOG) Breast Cancer Study Group under public fund (National Cancer Center Research and Development Fund).
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative
|
Herceptin (trastuzumab) • Perjeta (pertuzumab)
6ms
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
P1, N=45, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Apr 2021 --> Jul 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
|
UAB30
6ms
Clinical • Enrollment change • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD133 • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • ROR1 expression • PGR negative
|
paclitaxel • cirmtuzumab (UC-961)
6ms
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies (clinicaltrials.gov)
P1, N=60, Recruiting, Fred Hutchinson Cancer Research Center | Trial completion date: Dec 2036 --> Dec 2037 | Trial primary completion date: Dec 2021 --> Dec 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1)
|
EGFR mutation • HER-2 negative • ALK mutation • ROR1 expression
|
JCAR024
6ms
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer (clinicaltrials.gov)
P2, N=30, Completed, Northwestern University | Recruiting --> Completed | Trial completion date: Jun 2023 --> Jan 2021
Clinical • Trial completion • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 overexpression • ER positive • HER-2 negative • ER negative
|
Imfinzi (durvalumab) • tremelimumab (CP-675206)
6ms
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial primary completion date: Mar 2021 --> Jun 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative
|
methotrexate IV
6ms
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (clinicaltrials.gov)
P2, N=64, Recruiting, NSABP Foundation Inc | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Oct 2020 --> Oct 2021
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HR negative
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide intravenous
6ms
Bicalutamide in Treating Patients With Metastatic Breast Cancer (clinicaltrials.gov)
P2, N=28, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Mar 2021 --> Mar 2022
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
AR positive • PGR negative
|
bicalutamide
6ms
Clinical • Enrollment change • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)
|
HR positive • HER-2 negative
6ms
Clinical • Enrollment change • Combination therapy
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ER (Estrogen receptor) • PGR (Progesterone receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • BRAF mutation • BRAF V600 • HER-2 negative • RET mutation • ER negative • PGR negative
|
Opdivo (nivolumab) • DF6002
6ms
CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells. (PubMed, PLoS One)
The CK1 inhibitor, D4476, partly mimicked the CSNK1G2 knockdown effect in ER+ breast cancer cells, but with a broader repression ranging from PI3K/AKT/mTOR/S6K to ERK signaling. Collectively, these results suggest that CSNK1G2 plays a key role in sensitizing TAM toxicity in ER+ and ER- breast cancer cells via differently regulating PI3K/AKT/mTOR/S6K and ERK signaling.
Journal
|
ER (Estrogen receptor) • CD44 • CD2 (CD2 Molecule)
|
ER positive
|
tamoxifen
6ms
The analog of cGAMP, c-di-AMP, activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cells. (PubMed, Apoptosis)
c-di-AMP induces IRF-3 translocation to mitochondria and initiates Caspase-9 mediated cell death and inhibits clonogenicity of triple-negative breast cancer cells. This study suggests that c-di-AMP can activate and modulates STING pathway to induce mitochondrial mediated apoptosis in estrogen-receptor negative breast cancer cells.
Journal
|
ER (Estrogen receptor) • STING (stimulator of interferon response cGAMP interactor 1) • CASP9 (Caspase 9)
|
ER negative
6ms
Genetically predicted bipolar disorder is causally associated with an increased risk of breast cancer: a two-sample Mendelian randomization analysis. (PubMed, Ann Transl Med)
Our findings provided evidence for a causal relationship between genetically predicted BD and an increased risk of breast cancer overall. Further studies are warranted to investigate the underlying mechanism.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
6ms
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative • ER negative
6ms
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative • ER negative
6ms
Clinical • Phase classification • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Keytruda (pembrolizumab) • Zejula (niraparib)
6ms
PALAVY: Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (clinicaltrials.gov)
P2, N=96, Not yet recruiting, Abramson Cancer Center of the University of Pennsylvania
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR positive
|
Ibrance (palbociclib) • Bavencio (avelumab) • hydroxychloroquine
7ms
Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer. (PubMed, Biomolecules)
It is upregulated upon treatment with zoledronate and this effect reduces invasion of breast cancer cells. In our recent work, we demonstrated that the syndecan-4 level was reduced after trastuzumab treatment. Similarly, syndecan-4 levels are also reduced after panitumumab treatment. Together, the data found suggest that syndecan-4 level is crucial for understanding the changes involving in malignant transformation, and also demonstrate that syndecan-4 emerges as an important target for cancer therapy and diagnosis.
Review • Journal
|
ER (Estrogen receptor) • SDC4 (Syndecan 4)
|
ER negative
|
Herceptin (trastuzumab) • Vectibix (panitumumab) • zoledronic acid
7ms
Vaccination of Triple Negative Breast Cancer Patients (clinicaltrials.gov)
P1/2, N=102, Recruiting, University of Arkansas | Phase classification: P2 --> P1/2 | Trial completion date: Nov 2021 --> Nov 2024 | Trial primary completion date: Nov 2021 --> Nov 2023
Clinical • Phase classification • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
paclitaxel • doxorubicin hydrochloride
7ms
Multiparametric MRI as a Non-Invasive Biomarker of the Tumor Microenviroment (clinicaltrials.gov)
P=N/A, N=10, Recruiting, Laura Kennedy | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • HR negative
7ms
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy (clinicaltrials.gov)
P=N/A, N=1, Completed, Pfizer | Not yet recruiting --> Completed | Trial completion date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2020
Clinical • Clinical data • Trial completion • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • PGR positive • PGR negative
|
Ibrance (palbociclib)
7ms
New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • ER negative
|
Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
7ms
Outcomes After Accelerated Partial Breast Irradiation in Women With Triple Negative Subtype and Other "High Risk" Variables Categorized as Cautionary in The ASTRO Guidelines. (PubMed, Front Oncol)
The data from this study suggests that women possessing high risk features are at no more meaningful risk for recurrence than other patients considered to be acceptable for APBI treatment. However, the finding of axillary recurrence in patients with triple negative breast cancer does warrant a degree of caution in proceeding with accelerated partial breast irradiation technique in this patient group.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER negative
7ms
[VIRTUAL] Enhancement of the antiproliferative and cytotoxic effect of AgNPs in combination with chemotherapy drug tamoxifen in ER+ and ER- breast cancer cell lines (ACS-Sp 2021)
This effect was correlated with the cells' morphological changes, the induction of cell death by apoptosis, and an increase in ROS generation. We demonstrated that AgNPs can potentiate the cytotoxic and antiproliferative effect of tamoxifen in breast cancer cell line MCF-7, while the cell line MDA-MB-231 that are no-responsive to this chemotherapeutic showed less genotoxic damage associated with the treatments.
Preclinical • Combination therapy
|
ER (Estrogen receptor)
|
ER positive • ER negative
|
tamoxifen
7ms
High IRF8 expression correlates with CD8 T cell infiltration and is a predictive biomarker of therapy response in ER-negative breast cancer. (PubMed, Breast Cancer Res)
We propose IRF8 expression as a potent biomarker not only for prognosis, but also for predicting therapy response in ER-negative BC phenotypes. Its expression in neoplastic cells also correlates with CD8 T cell activation and infiltration. Therefore, our results justify new efforts towards understanding mechanisms regulating IRF8 expression and how they can be therapeutically manipulated.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • IRF8 (Interferon Regulatory Factor 8) • STAT1 (Signal Transducer And Activator Of Transcription 1)
|
ER negative • CD8 expression • IRF8 expression
|
doxorubicin hydrochloride • cyclophosphamide intravenous
7ms
ExIST: LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
P2, N=10, Recruiting, Baylor Research Institute | Trial completion date: Aug 2021 --> Aug 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
Clinical • Trial completion date • Trial primary completion date
|
ER (Estrogen receptor)
|
ER negative
|
prexasertib (LY2606368) • samotolisib (LY3023414)
7ms
[VIRTUAL] Tumor-stroma Ratio is Associated with Miller-Payne and Pathological Response to Neoadjuvant Chemotherapy in HER2-Negative Early Breast Cancer (SSO 2021)
Therefore, the TSR is a promising biomarker in predicting neoadjuvant treatment outcome. Incorporating this parameter in routine pathological diagnostics could be worthwhile to prevent overtreatment and undertreatment.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 negative • ER negative
7ms
[VIRTUAL] Surgical Management of the Axilla in the Z1071 Era: Propensity-Score Matched Analysis of the NCDB (SSO 2021)
SLNB/TAD provides comparable survival outcomes to CAD in HER2+ clinically node-positive breast cancer pts after neoadjuvant chemotherapy.
HER-2 (Human epidermal growth factor receptor 2)
7ms
[VIRTUAL] Pathologic Complete Response and Survival After Neoadjuvant Chemotherapy in cT1-T2/cN0 HER2 Amplified Breast Cancer (SSO 2021)
In patients with cT1-2/N0 HER2-amplified breast cancer receiving NAC, multi-agent compared to single agent chemotherapy with HER2 targeted therapy was not associated with improved survival after adjustment for other clinical factors in either complete responders or those with residual disease. While this requires confirmation in randomized studies, de-escalated neoadjuvant chemotherapy might be safe in women who are candidates for adjuvant taxol while providing biologic risk stratification based on response.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HR negative
|
paclitaxel
7ms
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC (clinicaltrials.gov)
P1, N=5, Terminated, UNC Lineberger Comprehensive Cancer Center | N=20 --> 5 | Active, not recruiting --> Terminated; Funding withdrawn.
Clinical • Enrollment change • Trial termination
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive
|
exemestane • entinostat (SNDX-275)
7ms
Adipocytes Under Obese-Like Conditions Change Cell Cycle Distribution and Phosphorylation Profiles of Breast Cancer Cells: The Adipokine Receptor CAP1 Matters. (PubMed, Front Oncol)
These results indicate that the adipocyte secretome and CAP1 are mechanistically important for the proliferation of both ER-positive and ER-negative breast cancer cells, and potential signaling mediators were identified. These studies provide biological insight into how obesity-associated factors could affect breast cancer.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
7ms
Enrollment closed • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • Imlygic (talimogene laherparepvec)
7ms
Clinical • New trial • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4)
|
HR positive • HER-2 negative
7ms
XRCC5/6 polymorphisms and their interactions with smoking, alcohol consumption, and sleep satisfaction in breast cancer risk: A Chinese multi-center study. (PubMed, Cancer Med)
XRCC5 rs16855458 was associated with breast cancer risk, and XRCC6 rs2267437 was associated with the risk of ER-/PR- breast cancer. Breast cancer risk associated with XRCC5 and XRCC6 polymorphisms might vary according to alcohol consumption and sleep satisfaction, respectively, and merit further investigation.
Clinical • Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR negative
7ms
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers (clinicaltrials.gov)
P1/2, N=90, Recruiting, Sellas Life Sciences Group | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Dec 2020 --> Jan 2024
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • PGR (Progesterone receptor) • WT1 (WT1 Transcription Factor) • MUC16 (Mucin 16, Cell Surface Associated) • BRCA (Breast cancer early onset)
|
HER-2 negative • BRCA mutation • PGR negative
|
Keytruda (pembrolizumab) • Zeltherva (galinpepimut-S) • hydroxyurea
7ms
New trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • HR negative
7ms
DIMRISC-2: Diffusion-Weighted MRI for Breast Cancer Screening in Women With a Personal History of Breast Cancer (clinicaltrials.gov)
P=N/A, N=1694, Not yet recruiting, Seoul National University Hospital | Initiation date: Nov 2020 --> Jun 2021
Clinical • Trial initiation date
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PGR negative
7ms
TavIx: Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer (clinicaltrials.gov)
P3, N=762, Completed, UNICANCER | Active, not recruiting --> Completed | Trial completion date: Sep 2019 --> Sep 2020
Clinical • Trial completion • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • HR negative • PGR negative
|
5-fluorouracil • docetaxel • epirubicin • Ixempra (ixabepilone)
7ms
[VIRTUAL] Palbociclib (Cyclin-Dependent Kinases CDK4 and CDK6 Selective Inhibitor) Induced Grade 3 Interstitial Pneumonitis (ATS 2021)
Introduction: In postmenopausal women, Palbociclib is a selective cyclin-dependent kinase CDK4 and CKD6 inhibitor to treat hormone receptor-positive metastatic breast cancer in combination with Letrozole (Aromatase Inhibitor)...She received adjuvant chemotherapy, followed by Anastrozole, for five years...She was managed conservatively with discontinuation of Palbociclib, and IV steroids were initiated (20 mg dexamethasone daily)...On the day of discharge, she was discharged on PO Prednisone dose 0.5mg/kg for six weeks along with oral Bactrim full dose three times a week for PJP prophylaxis...Rarely Palbociclib is associated with interstitial pneumonitis (incidence <1%) due to unknown mechanisms. The early identification of this side effect and treatment with immediate cessation of the drug and corticosteroids could be a life-saving measure, as is the case with our patient.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
|
HR positive • ER positive • HER-2 negative • PGR negative
|
Ibrance (palbociclib) • letrozole • prednisone • anastrozole • dexamethasone • trimethoprim/sulfamethoxazole
7ms
[VIRTUAL] HOXB7, a key transcriptional regulator in triple negative breast cancer progression (AACR 2021)
Our laboratory and others have accumulated a large body of evidence for the involvement of HOXB7 in various aspects of breast cancer progression: tamoxifen resistance, DNA repair, epithelial-mesenchymal transition, promotion of metastasis in a transgenic mouse model and human cells as well as angiogenesis suggesting a role for HOXB7 not only in the epithelium but also strongly implicating its control on the microenvironment of the tumor. In addition, CXCL1 and IL-8 signaling pathway by Reparixin, an inhibitor of the CXCR1/2 abrogated the tube formation and migration induced by MDA-MD-231-HOXB7 cells. These findings implicate IL-8 and CXCL1 signaling as a critical event in HOXB7 overexpression TNBC growth and metastasis via crosstalk between cancer cells and stromal components.
ER (Estrogen receptor) • IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • ARG2 (Arginase 2) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • ROBO3 (Roundabout Guidance Receptor 3) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
ER positive • ER negative
|
tamoxifen • reparixin (DF 1681Y)
7ms
[VIRTUAL] Tumor mutation burden of Egyptian breast cancer patients based on next generation sequencing (AACR 2021)
the preliminary findings of our studied sample set revealed that level of TMB in Egyptian BC patients is relatively low. Also, TMB value in hormone receptor positive and Ki-67 expression positive Egyptian BC patients is higher than hormone receptor negative and Ki-67 expression negative patients. Moreover, TMB value can be predicted based on the expression level of ER, PR, HER-2, and Ki-67.
Clinical • Next-generation sequencing • Tumor Mutational Burden • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TMB (Tumor Mutational Burden) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • ER positive • HER-2 negative • HER-2 expression • ER negative • HR negative • PGR positive • ER expression • PGR negative
7ms
[VIRTUAL] Nicotine promotes pre-metastatic niche formation in hormone receptor negative breast cancer through paracrine signaling in the tumor microenvironment (AACR 2021)
In addition, levels of LCN2 were significantly higher in the serum and urine of cancer patients and cancer-free healthy subjects who were smokers compared to non-smokers. Collectively, our results suggest a novel pro-metastatic role of nicotine-induced N2-neutrophils via secretion of LCN2 that facilitate metastatic colonization of hormone receptor negative breast cancer cells by supporting MET transition.
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
HR negative
7ms
[VIRTUAL] Elucidating the role of G0S2 in breast cancer (AACR 2021)
These data suggest that the role of G0S2 in breast cancer in dependent on ER-status, where G0S2 functions as a tumor suppressor in ER-positive breast cancer and a tumor promoter in ER-negative breast cancer. Molecular and genetic studies manipulating G0S2 and ER in various breast cancer contexts are ongoing and will help elucidate that precise role of G0S2 in breast cancer and provide clarity on the potential of G0S2 as a novel prognostic marker and therapeutic target.
ER (Estrogen receptor) • G0S2 (G0/G1 Switch 2)
|
ER positive • ER negative • G0S2 overexpression
7ms
[VIRTUAL] PD-L1 protein expression in Middle Eastern breast cancer predicts favorable outcome in triple negative breast cancer (AACR 2021)
In conclusion, we demonstrated strong association between PD-L1 and MSI in Middle Eastern BC patients and showed that PD-L1 overexpression on tumor cells was an independent favorable prognostic factor in TNBCs from this ethnicity. Overall, these findings might help in the development of more appropriate treatment strategies for BC in Middle Eastern population.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • MSI-H/dMMR • PD-L1 overexpression • ER negative • PGR negative
7ms
[VIRTUAL] A multi tumor survey of Nectin-4 expression to guide BT8009 indication selection (AACR 2021)
In all indications tested, a greater degree of Nectin-4 positivity was observed in the tumor cytoplasm as compared to tumor membrane. Breast and bladder cancer had the greatest frequency of Nectin-4 positivity. Subtype analysis in breast cancer identified enrichment of Nectin-4 expression in hormone receptor negative and human epidermal growth factor receptor 2 positive tumors.
HER-2 (Human epidermal growth factor receptor 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
|
HR negative • NECTIN4 expression
|
BT8009
7ms
[VIRTUAL] The clinical utility of BRCA1/2 pathogenic variants in breast cancer patient prognosis (AACR 2021)
This finding was replicated in the validation data (HR 2.53, 95% CI 1.23-5.22). Based on our findings, information on germline BRCA1 and BRCA2 pathogenic variants could be used to improve the prognostic estimation of breast cancer patients.
Clinical • BRCA Biomarker
|
ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
|
ER positive • ER negative
7ms
A meta-analysis of Watson for Oncology in clinical application. (PubMed, Sci Rep)
Treatment recommendations made by WFO and MDT were highly concordant for cancer cases examined, but this system still needs further improvement. Owing to relatively small sample size of the included studies, more well-designed, and large sample size studies are still needed.
Retrospective data • Journal
|
PGR (Progesterone receptor)
|
PGR negative
7ms
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer (clinicaltrials.gov)
P2b, N=37, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Sep 2021 --> Jun 2023 | Trial primary completion date: Sep 2020 --> Jun 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
AR positive
|
paclitaxel • Xtandi (enzalutamide)
7ms
Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Epacadostat (clinicaltrials.gov)
P1/2, N=60, Recruiting, BriaCell Therapeutics Corporation | Trial completion date: Dec 2020 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • PGR positive • PGR negative
|
epacadostat (INCB024360) • retifanlimab (INCMGA0012) • Intron A (interferon α-2b) • Bria-IMT (SV-BR-1-GM) • cyclophosphamide intravenous
7ms
[VIRTUAL] Inherited susceptibility to cancer: From family reunions to the front line of precision healthcare (AACR 2021)
Germline genetics influence somatic mutations and the evolutionary trajectory and life history of individual cancer genomes in diverse populations. Deeper understanding of the nature of this influence will allow us to explore innovative interventions to accelerate progress in precision health care and promote health equity.
BRCA Biomarker
|
ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • TNFSF10 (TNF Superfamily Member 10)
|
BRCA1 mutation • PALB2 mutation • ER negative
7ms
[VIRTUAL] Healthful and unhealthful plant-based diets and risk of breast cancer in U.S. women: Results from the Nurses’ Health Studies (AACR 2021)
This study provides evidence that adherence to a plant-based dietary pattern and, specifically, its healthful version, may reduce the risk of breast cancer, especially those that are more likely to be aggressive tumors. In contrast, a low-quality plant-based diet may be associated with an increased risk of ER-negative breast cancer.
Clinical
|
ER (Estrogen receptor)
|
ER negative
7ms
[VIRTUAL] Multicomponent epigenetic profiling of intermediate epithelial-to-mesenchymal states in triple negative breast cancer identifies distinct regulatory signatures (AACR 2021)
There was a stronger correlation between hmC and gene expression for differentially hydroxymethylated CpGs within accessible regions (R = 0.54, p < 0.01) than within non-accessible regions (R = 0.45, p = 0.02). Our results indicate both shared and distinct epigenetic profiles on the EMT spectrum at the cytosine and chromatin level regulate EMT processes and may be targeted to prevent the progression of EMT.
ER (Estrogen receptor) • PGR (Progesterone receptor) • CDH1 (Cadherin 1) • RUNX3 (RUNX Family Transcription Factor 3)
|
ER negative • PGR negative
7ms
[VIRTUAL] Estrogen receptor inhibition with tamoxifen mediates radiosensitization of ER+ breast cancer models (AACR 2021)
 Our data suggest that tamoxifen may be effectively used to radiosensitize ER+ breast tumors. This work also supports further clinical investigation of the timing of radiation for patients receiving endocrine therapy as concurrent use may be more effective than sequential.
Preclinical
|
RAD51 (RAD51 Homolog A)
|
ER positive • ER negative • ER expression
|
tamoxifen
7ms
[VIRTUAL] Ras-Raf-MEK-ERK signaling pathway: a novel target of ERRα and tamoxifen in TNBC cells (AACR 2021)
Our findings indicate that the Ras-Raf-MEK-ERK signaling pathway is a common target of both XCT-790 and tamoxifen. This provides a novel treatment strategy that should be investigated for the treatment of TNBC patients, opens the door for investigation of novel targeted therapies, and highlights the need for the use of prognostic markers to identify sub-populations that benefit from individualized treatment strategies.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative
|
tamoxifen
7ms
[VIRTUAL] Somatic variant burdenin benign breast disease and association with risk of subsequent breast cancer (AACR 2021)
This implicates a potential protective role for immune activation in BBD. Future directions will define the characteristics of the potentially protective immune response and its role in variant heterogeneity in a larger sample set, integrated with paired RNA sequencing to better understand the pathways involved and the relationship to immune infiltration.
PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
7ms
[VIRTUAL] Comparison of tumor profiles of second cancers among breast cancer survivors to first cancers in the SEER registries: A nationwide study (AACR 2021)
Screen-detectable second cancers were diagnosed at an earlier stage compared with first cancers. Further, second breast, uterine, and lung cancer had a more aggressive tumor profile compared to women with a similar type of first cancer suggestive of underlying biological differences between the two groups. It is plausible that more intensive screening strategies akin to screening recommendations for women at high risk of BC may be needed for survivors at risk for certain second cancers.
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
Oncotype DX Breast Recurrence Score®Test
7ms
[VIRTUAL] Paternal epigenetic regulation contributes to the prevention of estrogen receptor-negative mammary cancer with combined broccoli sprouts and green tea polyphenols consumption in transgenic mice. (AACR 2021)
Moreover, altered DNA methylation, histone methylation and acetylation levels were also observed. These results suggested that paternal exposure to BSp and GTPs may contribute to ER-negative mammary tumor prevention in their offspring through epigenetic regulations and the combined addition of bioactive botanicals could be a more promising approach for coping with breast cancer initiation and progression in humans.
Preclinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BMI1 (BMI1 proto-oncogene, polycomb ring finger)
|
ER negative
7ms
[VIRTUAL] Boosting immune surveillance by low-dose PI3K inhibitor facilitates early intervention of breast cancer (AACR 2021)
Prevention of estrogen receptor–negative (ER-) breast cancer is an unmet challenge, although tamoxifen and aromatase inhibitors can successfully decrease the incidence of ER-positive (ER+) breast cancer...Both genetic knockdown of PIK3CA or intervention with low-doses of a PI3K inhibitor (GDC-0941) prevented the dysplasia phenotype of semi-transformed human ER- mammary epithelial cells in 3-dimensional culture in vitro...In human ER- breast cancer, PI3K activation is correlated with significantly reduced CCL5, CXCL10 and CD8A expression, suggesting that the decreased CD8+ T-cell recruitment and escape of immune surveillance may contribute to ER- breast cancer development. In summary, our study indicates that low-dose PI3K inhibitor treatment may intervene early stage ER- breast cancer development by enhancing immune surveillance via CCL5/CXCL10.
ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • GZMB (Granzyme B)
|
ER positive • ER negative
|
tamoxifen • pictilisib (GDC-0941)
7ms
[VIRTUAL] Expression of androgen receptor splice variant, AR-V7, in high grade serous ovarian cancer (AACR 2021)
AR-V7 was not expressed in any specimen before or after platinum based chemotherapy suggesting it may not be a useful prognostic marker in the management of HGSOC. Further investigation into gynecologic malignancies with high AR expression and treated with androgen deprivation therapy may elucidate different results.
AR (Androgen receptor)
|
AR expression • AR-V7 expression • AR splice variant 7 • AR splice variant 7 expression
7ms
[VIRTUAL] Racial disparity in localized breast cancer: Pooled analysis of NSABP trials (AACR 2021)
AC/NAC included doxorubicin and cyclophosphamide, with or without a taxane... We observed that Black women with localized breast cancer had higher distant recurrence rates than White women. This and other reports suggest that factors other than social determinants of health may be contributing to racial disparities in breast cancer outcome/progression, most notably in ER-positive disease and patients with residual disease after NAC. Future research is needed to help delineate the biological differences that contribute to these observations.
Retrospective data
|
ER (Estrogen receptor)
|
ER positive • ER negative
|
doxorubicin hydrochloride
7ms
[VIRTUAL] Immune-cell profiling in breast cancer patients by race and triple negative breast cancer status (AACR 2021)
Future data analysis will focus on 18-gene tumor inflammation signature, 15+ proprietary gene expression signatures, and 14 immune cell type abundance signatures with a single sample and dataset analysis report, and automatic predictive algorithm training. With the recent FDA accelerated approval of PD-L1 inhibitor atezolizumab as a treatment for PD-L1-positive metastatic TNBC, the NanoString PanCancer IO 360 panel may provide the capability to both discover new biomarkers and create potentially predictive signatures for immunotherapies, which in turn may help improve minority health and reduce survival disparities.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
|
PD-L1 expression • ER positive • ER negative • PGR negative
|
Tecentriq (atezolizumab)
7ms
[VIRTUAL] Differences in somatic TP53 mutation type in breast tumors by race and receptor status (AACR 2021)
Larger cohorts are needed, in particular the AA cohort, to further elucidate some of these borderline findings. In summary, ER negative and TNBC breast tumors are more likely to have DNE TP53 mutations which could reflect biological processes.
ER (Estrogen receptor) • TP53 (Tumor protein P53)
|
TP53 mutation • ER negative
7ms
[VIRTUAL] Putative Bax activators GL0385 and GL0388 for targeted breast cancer therapy (AACR 2021)
Therefore, GL0385 and GL0388 are promising new advanced lead compounds towards the development of effective therapies for breast cancers and other cancers. Further investigation is warranted to fully explore their anti-cancer potential and mechanisms of action.
PARP Biomarker • IO biomarker
|
ER (Estrogen receptor) • BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
7ms
[VIRTUAL] Interleukin-17 and cytokine-related signalings are determinants for tumor immune microenvironment in triple-negative breast cancer: in silico integrated analysis (AACR 2021)
The tumor microenvironment with each immune cell component determines the impact on women's survival with TNBC. IS-high/SS-low TME portends a better overall survival. We propose further studies to examine if an immune/stromal state also predicts the response to immunotherapy.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • BRCA (Breast cancer early onset) • IL17A (Interleukin 17A)
|
ER negative
7ms
[VIRTUAL] A Utah Population Data Base Study of young women’s breast cancer outcomes by parity status (AACR 2021)
In this population level study from the state of Utah, a diagnosis of breast cancer within 5 years postpartum is a risk factor for metastasis and breast cancer-specific death that is independent of known clinical parameters, including ER status. The increased risk for poor outcomes is highest in stage I/II diagnoses. Relevance: For women with breast cancers classically considered as having good prognostic tumor features, i.e. stage I or II and ER-positive, a postpartum diagnosis is a dominant demographic feature of increased risk for metastasis and death.
Clinical
|
ER (Estrogen receptor)
|
ER positive • ER negative
7ms
[VIRTUAL] Treating estrogen receptor (ER)-negative and triple-negative breast cancer by targeting STAT3 signaling with putative STAT3 inhibitors (AACR 2021)
ENBCs do not respond to selective ER modulators such as tamoxifen...We recently developed a putative STAT3 inhibitor, HJC0152, and a series of HJC0152-based analogues as orally bioavailable STAT3 inhibitors...Our current research supports the notion that JMX0804 suppresses breast cancer growth by inhibiting breast cancer cell proliferation and inducing apoptosis via mediating STAT3 signaling. JMX0804 is currently undergoing further characterization for breast cancer metastasis and mechanisms of action as well as optimization to improve drug properties including potency and safety profile.
ER (Estrogen receptor)
|
tamoxifen • HJC0152
8ms
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov)
P1, N=19, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2020 --> Dec 2021
Clinical • Trial completion date • Combination therapy
|
TP53 (Tumor protein P53) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
|
TP53 mutation • TP53 expression • TP53 overexpression
|
Keytruda (pembrolizumab) • p53MVA
8ms
TRACERX-TNBC: Tracking Triple-negative Breast Cancer Evolution Through Therapy (clinicaltrials.gov)
P=N/A, N=149, Active, not recruiting, UNICANCER | Suspended --> Active, not recruiting | N=250 --> 149
Enrollment closed • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
8ms
BrUOG 351: PRE-OPERATIVE APBI USING NIBB (clinicaltrials.gov)
P=N/A, N=0, Withdrawn, Jaroslaw Hepel | N=26 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
8ms
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HR negative + HER-2 positive
8ms
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 negative • ER negative • PGR negative
|
carboplatin • Tecentriq (atezolizumab) • paclitaxel • epirubicin • cyclophosphamide intravenous
8ms
Signs of carcinogenicity induced by parathion, malathion, and estrogen in human breast epithelial cells (Review). (PubMed, Oncol Rep)
Cancer initiation has been associated with an increase in genomic instability, indicated by the inactivation of tumor‑suppressor genes and activation of oncogenes in the presence of malathion, parathion, and estrogen. In the present study, a comprehensive summary of the impact of OPs in human and rat breast cancer, specifically their effects on the cell cycle, signaling pathways linked to epidermal growth factor, drug metabolism, and genomic instability in an MCF‑10F estrogen receptor‑negative breast cell line is provided.
Review • Journal
|
ER (Estrogen receptor) • EGF (Epidermal growth factor)
|
ER negative
8ms
[VIRTUAL] Expression of RANK-c in ER-/HER2+ breast cancer cells affect aggressiveness through altering the NF-κB equilibrium (SG-BCC 2021)
RANK-c expression downregulated HER2 in SKBR3-RANK-c cells while in BT474-RANK-c cells HER2 was upregulated compared to mock transfected cells. Of note, in SKBR3-RANK-c cells, EGFR protein, p100 (NFKB2), phosphorylated p65 and phosphorylated ERK1/2 were significantly downregulated while BT474-RANK-c cells presented with the opposite phenotype. In the same way RANK-c expression negatively affected invasion and colony formation of SKBR3 cells while BT-474 were unaffected.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • NFKB2 (Nuclear Factor Kappa B Subunit 2)
|
HER-2 positive • ER positive • HER-2 expression • ER negative
8ms
[VIRTUAL] RANK-c expression in ER-negative breast cancer cells alters sensitivity to tyrosine kinase inhibitors (SG-BCC 2021)
Interestingly the two RANK-c expressing, ER-negative cells lines (231-RANK-c and SKBR3-RANK-c) presented with an opposite phenotype concerning TKI sensitivity upon treatment. 231-RANK-c RANK-c cells were unaffected by gefitinib, as judged by cell proliferation. Inversely, erlotinib decreased the proliferation rate of SKBR3-RANK-c cells while it did not affect the proliferation of 231- RANK-c cells.
ER (Estrogen receptor)
|
ER negative
|
erlotinib • gefitinib
8ms
Enrollment open • Clinical
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER negative • PGR positive • ER positive + HER-2 negative
|
Signatera™ • MammaPrint • EndoPredict®
|
Ibrance (palbociclib) • fulvestrant
8ms
Clinical • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive
|
MV-NIS
8ms
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
PD-L1 expression • HER-2 negative • ER negative • PGR negative
|
carboplatin • Tecentriq (atezolizumab) • paclitaxel • epirubicin • cyclophosphamide intravenous
8ms
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
LN-145
8ms
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=30, Active, not recruiting, Vanderbilt-Ingram Cancer Center | Trial completion date: Dec 2020 --> Dec 2021
Clinical • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 negative • AR positive • ER negative • PGR negative
|
Xtandi (enzalutamide) • taselisib (GDC-0032)
8ms
Abiraterone Acetate in Molecular Apocrine Breast Cancer (clinicaltrials.gov)
P2, N=34, Completed, UNICANCER | Active, not recruiting --> Completed
Clinical • Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 negative • AR positive
|
abiraterone acetate • prednisone
8ms
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer (clinicaltrials.gov)
P1, N=45, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Feb 2022 --> Apr 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
|
UAB30
8ms
Study on Androgen Receptor and Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=90, Recruiting, UNICANCER | Trial completion date: Sep 2021 --> Dec 2023 | Trial primary completion date: Mar 2020 --> Oct 2021
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 negative • AR positive
|
capecitabine • Nubeqa (darolutamide)
8ms
Stratification of Estrogen Receptor-Negative Breast Cancer Patients by Integrating the Somatic Mutations and Transcriptomic Data. (PubMed, Front Genet)
Furthermore, we selected six hub significantly mutated genes in the gene list which were also able to separate these patients. Our method provides a new and alternative method for integrating somatic gene mutations and expression data for patient stratification of estrogen receptor-negative breast cancers.
Clinical • Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
8ms
New P1 trial • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 negative • HR negative
|
carboplatin • paclitaxel • doxorubicin hydrochloride • Zejula (niraparib) • Neulasta (pegfilgrastim) • cyclophosphamide intravenous
8ms
Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention (clinicaltrials.gov)
P=N/A, N=80, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
Trial completion date • Trial primary completion date
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR negative
8ms
Pre-op Pembro + Radiation Therapy in Breast Cancer (clinicaltrials.gov)
P2; Not yet recruiting --> Recruiting | Initiation date: Aug 2020 --> Jul 2021
Enrollment open • Trial initiation date • Clinical • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • HER-2 negative • ER negative • FOXP3 expression • PGR negative
|
EndoPredict® • Immunoscore®
|
Keytruda (pembrolizumab) • carboplatin • paclitaxel • capecitabine • doxorubicin hydrochloride • cyclophosphamide intravenous
8ms
I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov)
P2, N=4000, Recruiting, QuantumLeap Healthcare Collaborative | Phase classification: P1 --> P2
Clinical • Phase classification
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • ER negative
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • Nerlynx (neratinib) • Kadcyla (ado-trastuzumab emtansine) • Perjeta (pertuzumab) • doxorubicin hydrochloride • irinotecan • Talzenna (talazoparib) • veliparib (ABT-888) • MK-2206 • Tukysa (tucatinib) • Jemperli (dostarlimab) • Libtayo (cemiplimab) • ganitumab (AMG479) • Turalio (pexidartinib) • ganetespib (ADX-1612) • trastuzumab duocarmazine (SYD985) • metformin • Cosela (trilaciclib) • Oraxol (oral paclitaxel/encequidar) • SD-101 • patritumab (U3-1287) • trebananib (AMG 386) • fianlimab (REGN3767) • ladiratuzumab vedotin (SGN-LIV1A)
8ms
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • PGR (Progesterone receptor) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
BRCA1 mutation • BRCA2 mutation • HER-2 negative • ER negative • PGR negative
|
Talzenna (talazoparib)
8ms
Crosstalk between miR-203 and PKCθ regulates breast cancer stem cell markers. (PubMed, Ann Hum Genet)
The study highlighted the negative feedback loop between miR-203 and its target PRKCQ and the interplay between them in regulating genes involved in BCSCs. The study also concluded "microRNA-mediated microRNA regulation" as an event in breast cancer cells.
Journal
|
ER (Estrogen receptor) • CD44 • SOX2 • NANOG (Nanog Homeobox)
|
ER negative • CD44 expression
8ms
Clinical • New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
cisplatin • gemcitabine • pucotenlimab (HX008)
8ms
A Population-Based Study of Genes Previously Implicated in Breast Cancer. (PubMed, N Engl J Med)
This study provides estimates of the prevalence and risk of breast cancer associated with pathogenic variants in known breast cancer-predisposition genes in the U.S. population. These estimates can inform cancer testing and screening and improve clinical management strategies for women in the general population with inherited pathogenic variants in these genes. (Funded by the National Institutes of Health and the Breast Cancer Research Foundation.).
Clinical • Journal • BRCA Biomarker
|
ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • CHEK2 (Checkpoint kinase 2) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CDH1 (Cadherin 1) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin))
|
ER positive • ER negative
8ms
TNBC-MERIT: RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID (clinicaltrials.gov)
P1, N=42, Active, not recruiting, BioNTech SE | Trial completion date: Nov 2020 --> Dec 2023
Clinical • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
BNT114 • IVAC_M_uID
8ms
Clinical • Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
LN-145
8ms
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • ER negative • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)
8ms
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
gemcitabine • capecitabine • Abraxane (albumin-bound paclitaxel) • Halaven (eribulin mesylate) • vinorelbine tartrate
9ms
Clinical study of first-line endocrine therapy for type ER+/PR+ and ER+/PR- advanced breast cancer. (PubMed, Ann Palliat Med)
ER+/PR+ advanced breast cancer patients had a better prognosis than ER+/PR- advanced breast cancer patients undergoing first-line endocrine therapy. In addition, we found that PR status was an independent predictor of first-line endocrine therapy responses in hormone receptor-positive HER2 negative patients.
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
9ms
Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer. (PubMed, Mol Cancer Ther)
Additionally, the use of Didox was also found to ameliorate the toxic myocardial effects of doxorubicin in vivo as measured by heart mass, left ventricular diameter, and serum troponin T levels. The data present a novel and promising approach for the treatment of TNBC that merits further clinical evaluation in humans.
Journal
|
ER (Estrogen receptor) • TP53 (Tumor protein P53) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)
|
TP53 mutation • ER positive • ER negative
|
doxorubicin hydrochloride • didox (NSC-324360) • Furtulon (doxifluridine)
9ms
Antiplatelet drug use and breast cancer risk in a prospective cohort of postmenopausal women. (PubMed, Cancer Epidemiol Biomarkers Prev)
Conclusions Low-dose aspirin was associated with a lower breast cancer risk only after several years of use, while ever use of clopidogrel was associated with a higher ER- breast cancer risk. Impact Antiplatelet drugs are not good pharmacological candidates for breast cancer prevention.
Clinical • Journal
|
ER (Estrogen receptor)
|
ER negative
|
clopidogrel
9ms
Denosumab as an add-on Neoadjuvant Treatment (GeparX) (clinicaltrials.gov)
P2, N=780, Completed, German Breast Group | Active, not recruiting --> Completed
Clinical • Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TNFRSF11A (TNF Receptor Superfamily Member 11a)
|
HER-2 positive • ER negative • PGR negative
|
Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • Abraxane (albumin-bound paclitaxel) • epirubicin • Prolia (denosumab) • cyclophosphamide intravenous
9ms
Clinical • Trial completion • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Imfinzi (durvalumab) • Abraxane (albumin-bound paclitaxel) • epirubicin • cyclophosphamide intravenous
9ms
[VIRTUAL] Functional Characterization of the Orphan Nuclear Receptor TLX in Triple Negative Breast Cancer (ENDO 2021)
For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO 2021.
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • HR positive • ER negative
9ms
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER negative • PGR negative
|
Baize’an (tislelizumab) • sitravatinib (MGCD516)
9ms
Nicotine promotes breast cancer metastasis by stimulating N2 neutrophils and generating pre-metastatic niche in lung. (PubMed, Nat Commun)
Moreover, natural compound, salidroside effectively abrogates nicotine-induced neutrophil polarization and consequently reduced lung metastasis of hormone receptor-negative breast cancer cells. Our findings suggest a pro-metastatic role of nicotine-induced N2-neutrophils for cancer cell colonization in the lungs and illuminate the therapeutic use of salidroside to enhance the anti-tumor activity of neutrophils in breast cancer patients.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3) • LCN2 (Lipocalin-2)
|
HR negative
9ms
[VIRTUAL] AR interacts with GATA3 to induce a luminal epithelial phenotype in breast cancer through regulation of lineage-restricted genes (LCC 2021)
Our findings indicate that AR and GATA3 interact in breast epithelial cells to drive the expression of luminal lineage markers and provide a mechanism underpinning breast cancers that are classified as having a luminal transcriptome irrespective of ER status.
ER (Estrogen receptor) • AR (Androgen receptor) • KRT19 (Keratin 19) • TP63 (Tumor protein 63) • GATA3 (GATA binding protein 3)
|
AR expression
9ms
Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
P2, N=12, Terminated, Sun Yat-sen University | N=30 --> 12 | Trial completion date: Jul 2023 --> Dec 2020 | Recruiting --> Terminated | Trial primary completion date: Jul 2022 --> Dec 2020; Difficulty accruing subjects the study accrual was closed
Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative • HR negative
|
Kinedak (epalrestat)
9ms
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IGFBP2 (Insulin-like growth factor binding protein 2) • IL10 (Interleukin 10) • CD4 (CD4 Molecule)
|
ER negative • PGR negative
|
Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab)
9ms
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score (clinicaltrials.gov)
P2, N=17, Completed, Yale University | Trial completion date: Jun 2020 --> Nov 2020 | Trial primary completion date: Jun 2017 --> Nov 2020
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HR negative • PGR positive • HR positive + HER-2 negative
|
everolimus
9ms
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Abraxane (albumin-bound paclitaxel) • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928)
9ms
Clinical • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
carboplatin • gemcitabine • Cosela (trilaciclib)
9ms
CABC: Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions (clinicaltrials.gov)
P=N/A, N=390, Recruiting, Cancer Registry of Norway | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER negative
9ms
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score (clinicaltrials.gov)
P2, N=17, Completed, Yale University | Suspended --> Completed | Trial completion date: Dec 2020 --> Jun 2020
Clinical • Trial completion • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HR positive • HER-2 negative • HR negative • PGR positive • HR positive + HER-2 negative
|
everolimus
9ms
Clinical • New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative
|
carboplatin • gemcitabine • moxifloxacin intravenous
9ms
neo-TN: Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
P2/3, N=310, Active, not recruiting, The Netherlands Cancer Institute | Trial primary completion date: Dec 2020 --> Jun 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative
|
carboplatin • paclitaxel • doxorubicin hydrochloride • thiotepa
9ms
NeoSTAR: Sacituzumab Govitecan In TNBC (clinicaltrials.gov)
P2, N=100, Recruiting, Aditya Bardia | N=50 --> 100 | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2022 --> Aug 2023
Clinical • Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • PGR negative
|
Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
9ms
Coffee consumption and risk of breast cancer: A Mendelian randomization study. (PubMed, PLoS One)
The results of this large MR study do not support an association of genetically predicted coffee consumption on breast cancer risk, but we cannot rule out existence of a weak association.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
9ms
Nanoscale flow cytometry for immunophenotyping and quantitating extracellular vesicles in blood plasma. (PubMed, Nanoscale)
When comparing plasma samples prepared by the same protocol, mammaglobin-a positive EVs were more abundant in estrogen receptor (ER) positive as compared to ER negative breast cancer patient plasma samples. This study demonstrates the capabilities of nanoscale flow cytometry for EV and small particle analysis in whole, unpurified, plasma samples, and highlights important technical challenges that need to be addressed when developing this technology as a liquid biopsy platform.
Journal
|
ER (Estrogen receptor) • SCGB2A2 (Secretoglobin Family 2A Member 2)
|
ER positive • ER negative
9ms
Kinase-substrate Edge Biomarkers Provide A More Accurate Prognostic Prediction in ER-negative Breast Cancer. (PubMed, Genomics Proteomics Bioinformatics)
Integrated analysis of the clinical and molecular data revealed the significant prognostic power of kinase-substrate node and edge features for both subtypes of breast cancer. Two promising kinase-substrate edge features, CSNK1A1-NFATC3 and SRC-OCLN, were identified for more accurate prognostic prediction in ER-negative breast cancer patients.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
9ms
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (clinicaltrials.gov)
P2, N=50, Active, not recruiting, Duke University | Recruiting --> Active, not recruiting | Trial completion date: May 2021 --> Aug 2021 | Trial primary completion date: Mar 2021 --> Jun 2021
Clinical • Enrollment closed • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Lynparza (olaparib) • Imfinzi (durvalumab)
9ms
KEYNOTE-162: Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (clinicaltrials.gov)
P1/2, N=122, Active, not recruiting, Tesaro, Inc. | Trial completion date: Mar 2020 --> Apr 2021
Clinical • Trial completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR negative
|
Keytruda (pembrolizumab) • Zejula (niraparib)
9ms
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
P1b, N=65, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • bintrafusp alfa (M7824) • entinostat (SNDX-275) • BN-Brachyury
9ms
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 amplification • HER-2 overexpression • ER negative
9ms
The chemical environmental pollutants BPA and BPS induce alterations of the proteomic profile of different phenotypes of human breast cancer cells: A proposed interactome. (PubMed, Environ Res)
These findings show new evidence that BPA and BPS exposure can contribute to breast cancer development and progression. Our results suggest that both BPA and BPS must be considered equally as outstanding risk factors for this pathology.
Journal
|
EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • CD44 • TGFB1 (Transforming Growth Factor Beta 1)
|
ER positive • ER negative
9ms
Clinical • Enrollment closed
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 expression
|
gemcitabine • capecitabine • Abraxane (albumin-bound paclitaxel) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Halaven (eribulin mesylate)
9ms
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC) (clinicaltrials.gov)
P2, N=8, Completed, NYU Langone Health | Recruiting --> Completed | N=52 --> 8 | Trial completion date: Jun 2025 --> Jan 2021 | Trial primary completion date: Jun 2025 --> Jan 2021
Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative
|
Opdivo (nivolumab) • Herceptin (trastuzumab) • paclitaxel • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide intravenous
10ms
CABC: Coping After Breast Cancer - a Randomized Clinical Trial With Two Digital Interventions (clinicaltrials.gov)
P=N/A, N=390, Not yet recruiting, Cancer Registry of Norway | N=834 --> 390 | Initiation date: Sep 2020 --> Jan 2021
Clinical • Enrollment change • Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER negative
10ms
Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer (clinicaltrials.gov)
P1/2, N=106, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021
Clinical • Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor) • PTEN (Phosphatase and tensin homolog)
|
HER-2 amplification • PIK3CA mutation • HER-2 negative • PTEN mutation • PIK3CA expression
|
Halaven (eribulin mesylate) • Aliqopa (copanlisib)
10ms
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HR positive • HER-2 expression • ER negative
|
Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
10ms
PROMETEO: Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (clinicaltrials.gov)
P1, N=30, Recruiting, SOLTI Breast Cancer Research Group | Trial primary completion date: Nov 2020 --> Dec 2021
Clinical • Trial primary completion date • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • PRF1 (Perforin 1)
|
HER-2 negative • PGR positive • PGR negative
|
Tecentriq (atezolizumab) • Imlygic (talimogene laherparepvec)
10ms
Niraparib + TSR042 In BRCA Mutated Breast Cancer (clinicaltrials.gov)
P2, N=62, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting
Clinical • Enrollment open • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • PGR (Progesterone receptor) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
HER-2 positive • BRCA1 mutation • BRCA2 mutation • HER-2 amplification • HER-2 negative • PGR positive • ER positive + HER-2 negative • PGR negative
|
Zejula (niraparib) • Jemperli (dostarlimab)
10ms
Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells. (PubMed, Breast Cancer Res Treat)
Our study demonstrates an inverse correlation between PAI-1 and ESR1/PGR levels, as well as overall patient survival in estrogen/progesterone-responsive human tumours. With a focus on breast cancer, our data identify oleuropein as a natural PAI-1 inhibitor and suggest that oleuropein-mediated PAI-1 destabilisation may confer clinical benefit only in ER-/PR- tumours.
Journal
|
ER (Estrogen receptor)
|
PAI1 expression
10ms
New trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
10ms
Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer. (PubMed, Sci Rep)
In ER-negative breast cancer and in TNBC mGluR1 protein expression is an unfavorable prognostic marker. This study provides rationale to explore mGluR1 as a novel target for breast cancer treatment, especially for the more aggressive TNBC.
Journal
|
ER (Estrogen receptor)
|
ER negative • ER expression
10ms
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis (clinicaltrials.gov)
P2, N=16, Recruiting, Wake Forest University Health Sciences | Trial completion date: Mar 2021 --> Mar 2022 | Trial primary completion date: Dec 2020 --> Mar 2021
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative
|
methotrexate IV
10ms
[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma (clinicaltrials.gov)
P2, N=24, Recruiting, University of Utah | Not yet recruiting --> Recruiting
Enrollment open
|
ER (Estrogen receptor)
|
ER positive • ER negative
10ms
Clinical • New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER negative • PGR negative
|
Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
10ms
Clinical • New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • IFNG (Interferon, gamma) • IL17A (Interleukin 17A)
|
HER-2 negative • ER negative • PGR negative
|
alpha-lactalbumin vaccine
10ms
Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib (clinicaltrials.gov)
P2, N=23, Recruiting, University of California, San Francisco | Trial primary completion date: Dec 2020 --> Dec 2021
Clinical • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 amplification • HER-2 overexpression
|
Herceptin (trastuzumab) • Nerlynx (neratinib) • loperamide
10ms
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2020 --> Nov 2021 | Trial primary completion date: Nov 2020 --> Nov 2021
Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • AR (Androgen receptor)
|
HER-2 negative • AR positive • ER expression
|
Keytruda (pembrolizumab) • Ostarine (enobosarm)
10ms
Clinical • Enrollment change
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
10ms
Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis (clinicaltrials.gov)
P2, N=45, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting
Clinical • Enrollment closed • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative • PGR negative
|
Tecentriq (atezolizumab)
10ms
[VIRTUAL] High Circulating Regulatory (FoxP3+) T Cells and TGF-β Predict the Response to Anti-PD-1 Immunotherapy in NSCLC Patients (IASLC-WCLC 2020)
Methods The patients with NSCLC (stage IIIB to IV) undergoing anti-PD-1 immunotherapy with either pembrolizumab (200 mg every 3 weeks) or nivolumab (2 mg/kg every 2 weeks) were enrolled in a part of a phase II clinical trial (NCT02607631) at Samsung Medical Center (Korea). The understanding of the clinical relevance of the tumor microenvironmental immunologic milieu might provide an important clue when designing novel strategies in cancer immunotherapy, however, blood based Treg cells might also provide alternative sources when tumor biopsy is not available. Therefore, Treg cells frequencies and TGF-β expression level might be used as blood-based biomarkers to predict the response of anti-PD-1 immunotherapy in advanced NSCLC patients.
Clinical • PD(L)-1 Biomarker • IO biomarker
|
IL2RA (Interleukin 2 receptor, alpha) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • PD-L1 overexpression
|
Keytruda (pembrolizumab) • Opdivo (nivolumab)
10ms
Expression of nuclear XIAP associates with cell growth and drug resistance and confers poor prognosis in breast cancer. (PubMed, Biochim Biophys Acta Mol Cell Res)
Remarkably, overexpression of XIAP, but not XIAP, conferred resistance to doxorubicin and increased cellular proliferative capacity...Consistently, multivariate analysis revealed nuclear, but not cytoplasmic XIAP, as an independent prognostic factor in hormone receptor-negative breast cancer patients. Altogether, our findings suggest that nuclear XIAP confers poor outcome and RING-associated breast cancer growth and chemoresistance.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
HR negative • BIRC5 expression
|
doxorubicin hydrochloride
10ms
EEF1A2 triggers stronger Erk mediated metastatic program in ER negative breast cancer cells than in ER positive cells. (PubMed, Life Sci)
We highlight the specific tendency of EEF1A2 to enhance invasive properties of cell lines in particular molecular subtype only. This sheds light on its selective role in regulating oncogenic processes in breast cancer and could explain its contradicting association with good survival, despite being an oncogene in a certain cohort of breast cancer patients.
Journal
|
ER (Estrogen receptor)
|
ER positive • ER negative
10ms
LUCY: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. (clinicaltrials.gov)
P3, N=256, Active, not recruiting, AstraZeneca | Trial completion date: Nov 2020 --> Jun 2021 | Trial primary completion date: Nov 2020 --> Jun 2021
Clinical • Trial completion date • Trial primary completion date • BRCA Biomarker • PARP Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • PGR (Progesterone receptor) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
|
HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive • BRCA mutation • PGR negative
|
Lynparza (olaparib)
11ms
FABP7 is a potential biomarker to predict response to neoadjuvant chemotherapy for breast cancer. (PubMed, Cancer Cell Int)
FABP7 is a potential favorable biomarker and predicts better response to NAC in breast cancer patients. Future study on the predictive value and detail molecular mechanisms of FABP7 in contribution to chemosensitivity in breast cancer is warranted.
Clinical • Journal
|
ER (Estrogen receptor) • CDH1 (Cadherin 1)
|
ER negative • CDH1 expression • CDKN1B expression
11ms
Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=42, Not yet recruiting, Thomas Jefferson University | Initiation date: Jul 2020 --> Dec 2020
Clinical • Trial initiation date • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • PD-L2 (Programmed Cell Death 1 Ligand 2) • PRAME (Preferentially Expressed Antigen In Melanoma)
|
PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • ER positive + PGR positive • PGR positive • PGR negative
|
Keytruda (pembrolizumab) • Bria-IMT (SV-BR-1-GM) • cyclophosphamide intravenous
11ms
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 (clinicaltrials.gov)
P1, N=219, Active, not recruiting, Infinity Pharmaceuticals, Inc. | Trial primary completion date: Dec 2020 --> Jun 2021
Clinical • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR • ER negative • PGR negative
|
Opdivo (nivolumab) • eganelisib (IPI-549)
11ms
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy (clinicaltrials.gov)
P2, N=35, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2020 --> Dec 2024 | Trial primary completion date: Jun 2020 --> Dec 2023
Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 negative
|
Keytruda (pembrolizumab)
11ms
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER negative
11ms
Clinical • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • PGR negative
11ms
Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer (clinicaltrials.gov)
P1/2, N=180, Active, not recruiting, Daiichi Sankyo Co., Ltd. | Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Sep 2020 --> Feb 2021
Clinical • Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HR positive • HER-2 negative • HER-2 expression
|
patritumab deruxtecan (U3-1402)
11ms
Clinical • Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative
|
Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Abraxane (albumin-bound paclitaxel)
11ms
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) (clinicaltrials.gov)
P1b, N=65, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
|
HER-2 positive • HR negative
|
Kadcyla (ado-trastuzumab emtansine) • bintrafusp alfa (M7824) • entinostat (SNDX-275) • BN-Brachyury
11ms
Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. (PubMed, Cell Death Differ)
Furthermore, we report that SPAG5 is a direct transcriptional target of TEAD/YAP/TAZ, and pharmacological targeting of YAP and TAZ severely reduces SPAG5 expression. Collectively, our data uncover an oncogenic feedback loop, comprising miR-10b-3p, SPAG5, and YAP/TAZ/TEAD, which fuels the aberrant proliferation of breast cancer.
Journal
|
ER (Estrogen receptor) • MIR10B (MicroRNA 10b)
|
ER negative
11ms
CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. (PubMed, Sci Rep)
Moreover, mice fed CDDO-Me demonstrated significant reductions in numbers of CD4 Foxp3 regulatory T cells within tumors. These results demonstrate for the first time that CDDO-Me relieves immunosuppression in the breast TME and unleashes host adaptive anti-tumor immunity.
Journal
|
ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • CCL2 (Chemokine (C-C motif) ligand 2) • IL10 (Interleukin 10) • FOXP3 (Forkhead Box P3)
|
ER negative • VEGFA expression
|
bardoxolone methyl (RTA 402)